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ABSTRACT
Direct post-translational control over a protein of interest (POI) can be exploited
by manipulating the cells protein quality-control systems responsible for either
intracellular turnover through ubiquitination (POI half-life) or repairing and degrading
misfolded proteins.1 In an effort to target and degrade a high value POI we selected the
enzyme human thymidylate synthase (TS) for post-translational degradation through
ligand-directed ubiquitination and hydrophobic tagging.
Thymidylate synthase catalyzes the reductive methylation of 2’-deoxyuridine
monophosphate (dUMP) to 2’-deoxythymidine monophosphate (dTMP). As the de novo
source of dTMP the regulation of intracellular TS is strictly controlled by ubiquitinindependent proteasomal degradation mediated by an internal TS-degron sequence.2,3
Using conventional peptide synthesis and the TS-directed antifolate, raltitrexed (RTX),
we designed a series of a high affinity RTX-directed conjugates that specifically recruited
TS to the von Hippel Linadau (VHL) E3 ligase in order to facilitate ubiquitin-dependent
proteasomal degradation. These protein suppression conjugates are known as
PROteolysis TArgeting Chimera’s (PROTAC). These conjugates were challenged against
TS and TS overexpressing cell lines with their inhibition and ubiquitination events
monitored by half-life and Western blot analyses. However, no evidence of ubiquitinmediated proteasomal degradation was found.
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Contrary to the reliance of ubiquitination by the PROTAC’s system, we sought to
simplify our approach and “tag” TS with a hydrophobic probe. The seminal driving force
behind protein folding and stabilization is the burial of core hydrophobic residues.4 While
these residues are critical to maintaining the native folding state, partial denaturation
results in their exposure, leading to incomplete folding events and proteasomal
degradation.5,6 In an effort to mimic this endogenous event and promote active TS
proteasomal degradation, we generated a small library of RTX linked hydrophobic tags
using the Kenner safety-catch handle under solid phase peptide synthesis. In this study
we found that the general length of both the linkage and surface area of the hydrophobic
tag were essential to growth inhibition of TS bearing cells. The implications of these
findings, with regards to both the synthetic endeavors and their respective biological
results, are discussed.
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CHAPTER 1
INTRODUCTION

1.0 THYMIDYLATE SYNTHASE: FUNCTION AND MECHANISIM
Since the early 90’s human thymidylate synthase (hTS) [EC 2.1.1.45] has been a
high profile drug target for colorectal cancer.7 A concerted effort has been made to
delineate the relationship between its structural biology and pharmacological potential, as
hTS is responsible for the de novo production of thymidine, a process which is invariably
highjacked by malignant cells and other tissue specific neoplasms. Through the tandem
coupling of the nucleoside 2’-deoxyuridine monophosphate (dUMP) and the cofactor
N5,N10-methylenetetrahydrofolate

(CH2H4PteGlu),

hTS

catalyzes

the

reductive

methylation of dUMP to produce one of the four nucleoside-phosphates necessary for
genetic inheritance: 2’-thymidine monophosphate (dTMP) (Figure 1.1).
The highly evolutionary conserved human thymidylate synthase is a 70 kDa
committed dimer complex with each monomer (35 kDa) interface consisting of an
extremely tight interaction between each of the two six-stranded β-sheets - one from each
subunit.8 The back walls of each active site, where the catalytic cysteine resides, sit at the
surface opposite of the β-sheet interface.8 Each catalytic cysteine occupies position 195
(Cys198 in E.coli) at the base of the fourth β-strand in the catalytic loop 181-197. Crystal
structures have shown the catalytic loop placing Cys195 outside the active site,
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Figure 1.1. A Representative schematic for the synthesis of deoxythymidine
monophosphate (dTMP) from deoxyuridine monophosphate (dUMP) by hTS. The
metabolic turnover of dUMP coupled with its cofactor, N5,N10methylenetetrahydrofolate (CH2H4PteGlu), to produce dTMP and dihydrofolate
(H2PteGlu), which is subsequently reduced by NADPH through dihydrofolate
reductase (DHFR). Its product, tetrahydrofolate (H4PteGlu) is used to regenerate
CH2H4PteGlu through a reaction with the PLP-dependent enzyme serine
hydroxymethyltransferase (SHMT) and the amino acid L-serine.

2

indicating that the conformer is inactive. In concert with this inactive conformation was
the disordered state of loop 108-129, which is perpendicular to the catalytic loop 181197.8 Conversely, upon ligand binding, loop 181-197 is rotated 180° toward the active
site pocket and inserts the nucleophilic Cys195 residue with a concomitant ordering of
loop 108-129 (Figure 1.2).9 The order and mobility of the two loops work in concert to
foment the catalytic turnover of dUMP. In between this dynamic mobility hTS forms an
asymmetrical alignment, which is believed to act as a guide for both substrates and assist
in docking with in the active site.
This shift in conformation subsequently renders the opposite monomer unit
incapable of binding substrates, hence, the binding of substrates to hTS creates a dynamic
active/inactive population. In another word, the concerted order (or disorder) of loops
181-197 and 108-129 renders each monomer as active or inactive.10 Post-substrate
binding, a significant structural adjustment occurs where specific active site residues are
repositioned toward the incoming ligands. The ordered sequential manner in which the
substrates bind relies upon the pyrimidine dUMP binding first, followed by the cofactor,
CH2H4PteGlu. Once the substrate and co-substrate are bound, hTS catalyzes the reductive
methylation of dUMP followed by the sequential release of H2PteGlu and the product,
dTMP (Figure 1.3).
Interestingly, hTS catalyzes the first step in the cyclic process devoted to the
transfer of single carbon moieties, which are found under three different oxidation states
of CH2H4PteGlu: formate, formaldehyde, and methanol. The transfer at the formaldehyde
oxidation state, which is equivalent to the transfer of a hydroxymethyl group, is catalyzed
by hTS as CH2H4PteGlu is in the correct oxidation state to transfer a hydroxymethyl

3

Figure 1.2. Active conformation of thymidylate synthase monomer (PDB 1HYV). The
four β-strands (yellow) generate a tight interface between monomer units. At the top
of the first β-strand resides the catalytically active Cys195, which is currently
positioned in the active state with both loops, 181-197 (red) and 108-127 (blue)
occupying the same active conformation.9

4

Figure 1.3. A pseudo-Cleland diagram illustrating the sequential ordered binding and
release of dUMP/CH2H4-PteGlu followed by H2-PteGlu/dTMP, respectively. (E
represents human thymidylate synthase).

5

group (originally from L-serine). Here hTS catalyzes the transfer of the single carbon unit
and a lone hydride from different sites of the cofactor CH2H4PteGlu. However, the final
product is methylated rather than hydroxymethylated, corresponding to a reduction of
dTMP and the subsequent oxidation of CH2H4PteGlu to H2PteGlu. The mechanistic
process is achieved through the dynamic alignment and realignment of the substrate and
co-substrate throughout a series of steps in the catalytic domain of hTS (Figure 1.4).
The steps demonstrating the mechanistic anatomy of TS were realized upon the
investigative efforts surrounding the 25 conserved residues within the active site.11
Contrary to the premise of nature conserving residues across multiple species, it was
determined that only five residues proved to be irreplaceable: Arg218 (dUMP
stabilization), Asp221 (cofactor stabilization), Cys198 (nucleophile in Michael Addition
to C6 of dUMP, intermediate I), Tyr146 (active base that abstracts C5 proton from
intermediate III), and Glu60 (cofactor elimination from ternary complex).11 The
guanidinium groups of four conserved arginine’s produce an electrostatic anchor that
surrounds the phosphate of dUMP in a tetrahedral arrangement, securing dUMP for the
impending arrival of the cofactor.11 In addition to stabilizing dUMP, Arg218 acts as a
physical “buttress” through the hydrogen bonds between its guanidinium head group and
two loops within the active site.
Formation of the ternary complex is accomplished upon cofactor binding, which
causes a conformational shift, directing segments of the primary structure to form the
core of the active catalytic binding site around the reactants through maximizing
hydrophobic interactions and sequestering the substrates from the bulk solvent.11 Hence,

6
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Figure 1.4. The catalytic mechanism for the reductive methylation of dUMP by hTS with the cofactor CH2H4PteGlu. (I) Cys195
covalently activates C6 of dUMP by nucleophilic Michael addition with concomitant ring-opening formation of the iminum at N5 of
the pterin ring. (II) Upon formation of the iminum ion, the enolate attacks the resulting Mannich base generating the covalent linkage
between the two substrates. (III) Tyr146 abstracts the C5 proton on dUMP reconstituting the active enolate. (IV) The enolate
subsequently collapses eliminating the covalent bridge and transferring the methylene moiety to C5. (V) Finally, a hydride-transfer
from C6 of the pterin ring reforms the C5-C6 unsaturation, releasing Cys195 and forming dTMP.1

the binding cavity isn’t fully formed until (i) dUMP is sequestered, (ii) a number of
hydrophobic side chains are within van der Waals contact with either the pterin ring
system (2-aminopteridin-4(3H)-one) or p-aminobenzylic acid/thiophene substituent of the
cofactor, (iii) electrostatic side chains or water-mediated hydrogen bond network has
coordinated with the cofactors glutamate(s), and (iv) Asp221 has coordinated with the
pterin ring and additional hydrogen bonds through amino acid side chains and water.11
The conserved binding mechanism, in which TS successfully mediates a convoluted
reaction coordinate, is paid through an entropic reduction mediated by cofactor binding
and its effects upon closing the active site, aligning the reactants, and solvent
sequestration.11

1.1 ANTIMETABOLITES OF THYMIDYLATE SYNTHASE
Antimetabolites are currently the most widely applied treatment for both viral
infections and cancer therapies. In general, they [antimetabolites] are analogs of natural
metabolites that either directly or indirectly play a role in the metabolism or biosynthesis
of DNA and RNA.12 Antimetabolites are of strategic importance regarding their
applications in cancer. This is due to the unmitigated proliferation that many cancers
exhibit in order to maintain their rapid and incongruous expansion.
As a malignancy develops, it requires a vast carriage of nutrients and a steady
source of carbon. In order to maintain this rate of expansion, cells located in the tumor
parenchyma establish aberrant vasculature networks, which act as industrial highways for
the import of carbon.13 The dramatic intake is complemented by increased DNA
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synthesis and replication, cell division, and overall tumor survival. Progression of tumor
growth correlates to altered genetic expression and gene-product production, a process
that is intrinsically relevant to the metabolic fate of folic acid and the genes encoding
their respective binding and import proteins.14 As the centerpiece in DNA/RNA
biosynthesis and repair, folic acid is an essential cofactor as demonstrated by its
supplementation for expecting mothers and its routine use as an antifolate in oncology
clinics.
Dietary folic acid is chiefly found in leafy green vegetables, fruits, legumes, and
liver. Upon ingestion, folic acid primarily accumulates in the intestine with adsorption
occurring in the jejunum. Here they are transferred across the apical membrane, as well
as in the kidneys, and released into circulation as 5-methyl tetrahydrofolate (5mTHF).15
The cellular acquisition of 5mTHF allows for the metabolic methylation of homocysteine
to produce methionine and H4PteGlu (THF). The cofactor THF is the responsible unit for
the one carbon donation in biosynthesis of the nucleoside dTMP.15
Of consideration to this research are the pyrimidine and folate (Vitamin B9)
analogs, which suppress the catalytic capacity of thymidylate synthase – the de novo
source of thymidine. In the absence of dTMP, inhibition of hTS leads to a reduction in
the intracellular thymidine pools disrupting DNA synthesis and leads to cell death – a
phenomenon known as ‘thymineless death.’16 This metabolic bottleneck represents a
prime opportunity for the development for chemotherapeutics directed at inactivating
hTS. Clinically, the most widely used anti-TS agent is the suicide inhibitor 5-fluorouracil
(5FU). It’s clinical presence was based on the observation that uracil metabolism was
used more widely in tumors than normal tissues, strongly indicating a potential
9

therapeutic opportunity.17 Post-systemic delivery, 5FU is anabolized as a pro-drug to its
active form 5-fluoro-2’-deoxyuridylate (FdUMP) within the cell. Here, FdUMP’s
cytotoxicity is realized by the irreversible ternary complex that forms upon is binding to
hTS. The inhibition of hTS depletes the dTMP pools and induces severe destabilization
of the other three deoxynucleotide pools through separate feedback controls.18
Ultimately, this perturbation fractures DNA synthesis and repair, allowing the cell to
initiate apoptotic events.
Consequently, the blockade induced by FdUMP also leads to increased levels of
dUMP’s precursor metabolite: dUTP. Both the 5FU intermediate FdUTP and dUTP can
be incorporated into DNA causing strand breaks while maintaining a relative “immunity”
from the action of nucleotide excision repair by uracil-DNA-glycosylase (UGD).18 While
it appears that FdUMP possesses more than one mechanism to halt hTS turnover,
thymidylate kinase can salvage resident thymidine pools through phosphorylation to
reinstate dTMP, thus circumnavigating any intracellular depletion or inactivated hTS and
yielding a mechanism of resistance.
The over all response rates under the administration of single anticancer agent are
typically low and, in colorectal cancer (CRC), are approximately 10-15% with 5FU.19
Combining therapies to increase the therapeutic response to CRC and surpass potential
routes of resistance has dramatically improved 5FU’s intrinsic value. Specifically, the use
of antifolates has compounded the efficacy of 5FU’s and as a result it has maintained its
clinical presence from the late 1950’s. The cooperatively displayed by co-administration
of antifolates and 5FU lies within the cells requirement to maintain high endogenous
levels of reduced folate (CH2H4PteGlu). In order to maintain optimal binding conditions
10

of FdUMP to hTS the antifolate Leucovorin (LV, 5’-formyltetrahydrofolate) was
administered to supplement the intracellular expansion of reduced folate. Uptake of LV is
mediated by the reduced folate carrier (RFC) and is then subsequently (poly)glutamylated
by folylpolyglutamate synthetase (FPGS). This enzyme, FPGS, affixes multiple glutamic
acid residues to the gamma-carboxylate of LV, which serves to increase the solubility of
LV and prevent premature export.20 Moreover, the addition of glutamic acid residues to
LV, and other notable reduced folate analogs, enhances the stability of the
hTSFdUMPLV complex. It was shown in large meta-analyses of CRC that while the
LV/FdUMP co-administration generated excellent response rates, this didn’t translate in
any significant extension of survival.21
In order to circumvent the deleterious effects of fluoro-pyrimidine resistance,
alternate hTS-targeting strategies were developed and focused on TS cofactor analogs.
Structural analogs of CH2H4PteGlu were designed around modification of the pterin ring
system, the number of methylene spacers between the ring system and the central
aromatic unit, and to a lesser extent, the modification of the terminal glutamic acid
moiety (Figure 1.5).
Raltitrexed (RTX, Tomudex or ZD1694) is a specific quinazolinone inhibitor of
hTS that demonstrated high affinity for hTS and improved cellular retention in addition
to low off-target activity when compared to its hTS analog counterparts (Figure 1.5).
Clinically, RTX showed promising results against breast, pancreas, hepatic, gastric, and
CRC with response rates ranging from 14-30%.22 Curiously, as a single therapeutic in a
CRC trial, RTX yielded a slightly lower median survival when compared to 5FU despite
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Figure 1.5. Antifolate inhibitors of thymidylate synthase and their respective halfmaximal inhibitory concentrations (R = Glutamic Acid).
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producing a superior toxicity profile.23 Nonetheless, as of the fall of 2014 there five
active clinical trials registered with the clinical trials database, Clincialtrials.gov, all of
which pair the co-adminstration of RTX with taxanes, platins, and radiation therapy or a
combination of angiogenic inhibitors, platins, and 5FU.
Raltitrexed was closely modeled after CB3717. Despite holding great promise as
an hTS inhibitor, CB3717 demonstrated life-threatening nephro and dose-limiting hepatic
toxicity, prematurely terminating its clinical development.20 Synthetic alterations of
CB3717 resulted in the rational design of RTX, which formed the ternary complex
hTSFdUMPRTX (Figure 1.6). Modifications of CB3717 included replacing the 2’amino group on the pterin ring, the methylenepropargyl at N10, and the benzene ring
system with two methyl groups and thiophene moiety, respectively (Table 1.1) These
modifications altered the compounds partition coefficient, which improve aqueous
solubility and reduced it to a benign nephrotoxicity profile. As with CB3717, RTX is a
structural analog of CH2H4PteGlu, but it lacks the key methylene moiety involved in
dTMP synthesis and therefore, it cannot participate in DNA synthesis or in its inhibitory
action, which is dependent upon dUMP accumulation.20
Raltitrexed is transported into the cell through the RFC as shown by its resistance
to enter cells (cell line L1210:1565) with impaired RFC function. Once inside the cell
RTX undergoes γ-polyglutamylation processing by FPGS where glutamic acid residues
are sequentially ligated via γ-linkages to the gamma-carboxylate of RTX. Against cell
lines unable to polyglutamylate reduced folates, the IC50 of RTX increased from 0.009 to
>100 µM, demonstrating the synergistic relationship between γ-polyglutamylation and
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Figure 1.6. Ternary structure of Thymidylate synthase monomer (PDB 1HYV), RTX,
and dUMP. At the base of the binding pocket, C6 of dUMP is covalently attached to
the sulfhydryl of Cys195 (magenta). Directly above dUMP is the planar face of the
quinazolinone ring system of RTX, which sits directly above and offset of the
nucleosides ribose. The thiophene and glutamic acid moiety of RTX are rotated 90°
with respect to the quinazolinone and 45° into the plane of the crystal structure. The
catalytic loop (residues 181-197) is in red.9
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Table 1.1. Relationship between the structural substitutions in raltitrexed and their
corresponding effects upon cellular uptake by the RFC and polyglutamylation as
measured by growth inhibitory properties compared to ICI 198583 and CB3717.

ID

C2

C7

N10

R1

R2

R3

Aryl
Group

Growth Inhibition, IC50 (µM)
L1210:1565 L1210:MB3
L1210
(RFCneg)
(FPGSneg)

RTX
2-NH2
7-CH3

CH3 H CH3
NH2 H CH2
CH3 CH3 CH3

Thiophene
Thiophene
Thiophene

0.009
0.72
1.6

0.92
0.5
43

70
94
9

ICI 198583
CB3717
7-CH3

CH3 H PgA
NH2 H PgA
CH3 CH3 PgA

Benzene
Benzene
Benzene

0.13
5.5
0.2

8
5.5
8

2.7
13
0.6
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antifolate potency.24 Notably, it was determined that within a 30-minute window roughly
90% of the drug was in mono-triglutamate form. After 24-hours only 30% of the tritiated
material was lost with the remaining consisting of tetra, penta, and hexaglutamate
forms.20 This concludes that the rate of FPGS processing is faster than rate of RTX export
and it estimates that the number of γ-glutamate associated with RTX is determining factor
in prolonging drug sequestration. It was noted that if the cells were resuspended in fresh,
drug-free media for 4 hours after the 24-hour incubation period that 40% of TS activity
returned. This may be interpreted in two ways: (a) the FPGS process was retarded, thus
the rate of processing was slowed; and (b) that although the γ-polyglutamate forms of
RTX enable cellular retention, constant drug exposure may be required.20 Nonetheless,
the mixed noncompetitive inhibition exhibited by RTX sees a dramatic improvement in
inhibitory potency (hTS affinity) with the addition of each corresponding γglutamylation.
The therapeutic value of RTX lies in its ability to maintain an intracellular
presence, thus increasing tissue residency. The result of which has been attributed to the
4-7 γ-connected glutamic acid residues to RTX.

Using ecTS (E. coli Thymidylate

Synthase) and a tetraglutamate analog of CB3717 Kamb et al. showed that
polyglutamylation alters the kinetics of ligand binding through minimal hydrogen
bonding and van der Waals contacts; although the majority of these contacts were
devoted to Glu-1 (glutamic acid) via a water-mediated hydrogen bond network to ecTS.
Both Glu-2 and Glu-3 (Glu-4 density was ambiguous) were found to be loosely fit,
suggesting that the γ-polyglutamyl tail is largely mobile and didn’t rely on any specific
ligand-protein interaction.25 This is likely due to the random-coil formation that
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polyglutamate peptides adopt at physiological pH. Therefore, a high entropic threshold is
likely pronounced during the formation of the ternary complex. Interestingly, the overall
fold improvement regarding the number of glutamic acid residues added with respect to
TS inhibition were found to vary between species.25

1.2 UBIQUITIN-INDEPENDENT PROTEOSOMAL DEGRADATION
The homeostasis of intracellular protein levels is primarily maintained by the
proteasome. Located in both the cytosol and the nucleus, the proteasome acts as a
disposal system responsible for destroying unwanted, aged, over saturated, and misfolded
proteins that, if left unregulated, would generate a toxic cellular environment. However,
its spatial and temporal control of key cellular cycles and regulatory system substrates is
its prime directive. Hence, cell division, environmental stress response, and apoptosis are,
in part, under the direction of the proteasome. Although the physical function of the
proteasome is proteolysis, it is a member of a much more complex and diverse system of
protein quality assurance.
It’s generally assumed that substrates are polyubiquitylated, via the covalent
linkage to ε-amino group of the substrates lysine, through a series of enzymes-complexes
that ultimately designate proteins for direct degradation (Figure 1.7). The proteasomeubiquitin system (UPS) possesses an additional layer of organizational molecularrecognition systems that are independent of degradation. Monoubiquitylation, for
example, is necessary for the trafficking of proteins, receptor internalization, virus
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Figure 1.7 General mechanism for ubiquitin-dependent proteasomal degradation. The
first step involves the E1 enzyme, Ube1, activation (via ATP) of ubiquitin (Ub)
through the conjugation of a free cysteine on E1 and the carboxy terminus of Ub.
Once activated, one of the 30-members of the E2 enzyme family can either directly
transfer the Ub unit to the protein of interest (POI) or interact with one of the 700
substrate-specific E3 ligases through two avenues: (i) the E3 ligase can directly
conjugate to the activated Ub and ubiquitinate the POI, (ii) the E3 ligase can form a
complex with E2-Ub where it facilitates the transfer of Ub from E2 unit to the POI.
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budding, and histone modification.26-29 Moreover, the ubiquitin-proteasome relationship
may also require adaptor proteins or molecular chaperones in order to corroborate
substrate identity as post-translational modifications substantially alter the proteome’s
diversity.30
Contrary to ubiquitin-dependent proteasomal degradation pathway(s) there exists
a small population of protein substrates that undergo proteasome recognition, but without
involvement of the complex network of activating and ligating enzymes. This subset of
degradation targets is independent of ubiquitin conjugation and therefore undergoes
ubiquitin-independent proteasomal degradation. Thymidylate synthase (TS) is a nonubiquinated proteasomal substrate that falls directly into the same aforementioned
category as Ornithine decarboxylase (ODC), calmodulin, p53 tumor suppressor protein,
and the CDK inhibitor p21Cip1.31-34
In an unbound state the half-life of hTS is approximately 6-10 hours. However,
inhibitors such as FdUMP and RTX stabilize the ternary complex and extend the
enzyme’s half-life to 20-24 hours, presumably altering the proteasome’s capacity to
degrade TS. This phenomenon was initially attributed as the result in an autoregulatory
response mechanism due to the exposure of the previously mentioned TS inhibitors. It
was postulated that exposure to TS inhibitors resulted in a 2-4 fold induction of enzyme
as a result of disrupting hTS-mRNA complex, thus blocking translational repression and
facilitating translational progress presenting a mechanism of resistance.35 It was found
that fluoropyrimidines do not alter ribosome binding to TS mRNA. Nor did altering the
binding domain of mRNA for the ribosome affect induction of TS.36
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The particular structural features of the N-terminus of TS, which is extended in
mammalian TS, appeared to regulate the enzymes intracellular half-life through
ubiquitin-independent proteasome degradation with 26S regulatory complex.37 Further
investigation confirmed the ubiquitin-independent proteolysis of the TS polypeptide
through site-directed modification of all internal lysine’s generating a ‘lysineless’ TS via
a K→R modification.
Under the lysineless mutant, administration of FdUMP still yielded an inhibitory
ternary-complex, thus the catalytic activity of TS was retained; additional evidence of its
ubiquitin-independence was corroborated under proteasomal inhibitors where the wtTS
half-life was restored upon their administration.38 Structurally, the intrinsically disordered
region (IDR) of the N-terminus is comprised of 45 residues possessing a proline-rich
region spanning positions 9-15 (9PRRPLPP15) and 24-27 with two-conserved arginine’s
at positions 10-11. Downstream of the flexible domain is a highly conserved amphipathic
15-residue α-helix (hA) from residues 31-45. Although hA functions as a structural
scaffolding in tandem with the IDR rather than in a sequence specific manner.39
Together, these 45 residues function as an independent degradation signal or degron
sequence.2
Although the domain is highly disordered, and therefore not found in crystal
structures, deletion of the degron sequence does not abrogate its catalytic activity, but
instead stabilizes the enzyme. Certain residues were found to possess critical features that
supported its ability to act as a degradation signal. Located at the penultimate position of
the N-terminal polypeptide lays a proline, which with the exception of M. musculus, is
conserved in mammals, and whose substitution only serves to stabilize TS (except under
20

Pro2→Gly2 or Pro2→Val2 point mutations).

Hence, the degron sequence requires

proline in the second position, and to a lesser extent, valine or glycine.3 TS also
undergoes post-translational excision of the Met initiator, but doesn’t experience N-αacetylation (it’s noted that acetylation of the N-terminal residue inhibits ubiquitylation
and thus, proteasomal degradation40-42) of the N-terminal amino acid leaving Pro2 free.
Conversely, Pro2→Leu2 or Pro2→Ala2 substitutions promote acetylation and stabilize
the TS polypeptide. This strongly suggests that the absence of acetylation and the
presence of proline at the penultimate position are critical to the intracellular half-life of
TS.3
Further evidence of the critical nature of the arginine dipeptide was demonstrated
through the half-life analyses of phylogenically related TS. Lacking this motif, arginine
point mutations were introduced to the N-terminus of cow, rabbit, platypus, and
armadillo TS where they demonstrably converted the N-termini of non-primate TS into
active degrons. Thus, the absence of the Arg-Arg motif is responsible TS stability in
these species.2 Taken together, the hTS degron functions as a bipartite degradation
system composed of two domains within the N-terminus: the IDR, which possesses the
critical residues Pro2 and 9-15 (9PRRPLPP15), along with the preceding α-helix. Both
domains are required and are the key determinants in the post-association steps leading to
the ubiquitin independent proteasomal processing of hTS.43
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1.3 TARGETING AND HYDROPHOBIC TAGGING OF CELLULAR PROTEINS
As with any intracellular regulatory system, its spatial and temporal control can
be subjected to ‘reprogramming’ through tumorigenesis. Of particular interest are the
established systems that manage protein turnover in order to maintain a healthy proteome
and modulate protein homeostasis. The strict regulation of protein turnover is typically
mediated by the proteasome and its ancillary system of substrate-specific ligases and
ubiquitin-conjugation enzymes colloquially referred to as the Ubiquitin-Proteasome
System (UPS).
The UPS asserts posttranslational control through four distinct mechanisms: (i)
activation of ubiquitin in an ATP-dependent reaction to the ubiquitin-activation enzyme
(E1), (ii) conjugation (or transfer) of ubiquitin to the ubiquitin-conjugation enzyme (E2)
from E1, (iii) ligation of ubiquitin to the substrate-specific ligase (E3) from E2 with
concomitant identification of the substrate by the E3 ligase, and lastly (iv) translocation
and proteolysis of the substrate via the proteasome. This indispensable identification and
degradation system governs cell cycle progression, apoptosis, DNA double-strand repair,
and angiogenesis, which are, notably the primary systems which cancer appropriates to
modulate its own malignant proliferation.44-48
Reports correlating cancer and the involvement of the E1 and E2 enzymes are
sparse. However, a large body of research has clearly linked the deregulation of the E3
ligases to multiple forms of disease and cancer.49-52 Checkpoint activation, cell-cycle
progression, and apoptosis are all potential points of oncogenic manipulation where the
E3-Ub machinery is readily commandeered, making it a therapeutic target.53,
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54

An E3

ligase of particular interest is the modular Skp-Cullin-F-box (SCF) or SCF complex. This
Ub-E3 ligase is composed of a heterotetrameric complex consisting of a Cullin subunit
Cul1, which forms a u-shaped complex that simultaneously interacts at its N-terminus
with the adaptor protein Skp1 (S-phase-kinase-associated protein-1), and its C-terminus
with the Rbx1: an ancillary zinc-binding RING finger where the E2 conjugating enzyme
docks. The final component, the F-box, is tethered to Skp1 and functions as an adaptor
protein where it recruits the POI and supply’s substrate specificity.55
Asserting control over the SCF complex via external tunable pharmacological
agents has provided a unique opportunity to control protein function through these
external posttranslational modifications. This technology has been developed by a
number of investigators. Crews et al. have pioneered some of the more simplistic and
facile protein degradation technologies.56-59 Using the SCF complex with the mammalian
F box protein (FBP) β-TRCP/E3RS (SCF -TRCP), they were able to target and promote
β

Ub-directed degradation of an off target POI: methionine aminopeptidease-2 (MetAP-2)
[60].
This was accomplished due to the intrinsic capability of SCF -TRCP to identify a
β

10-residue amino acid signal located on IκBα, a negative regulator of the transcriptional
modulator NFκB. Upon environmental inflammation, SCF -TRCP promotes Ub-directed
β

degradation of IκBα, thus activating NFκB.61 The inflammatory response induces
IκBα kinase (IKK) to phosphorylate both serines within the 10-mer-signal peptide of
IκBα , thus promoting its [phosphorylated IκBα] complexation with β-TRCP.62-64
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The IκBa phophopeptide (IPP) can be used recruit β-TRCP to the SCF -TRCP
β

complex. To determine if the SCF -TRCP complex could successfully target and degrade
β

MetAP-2, a high affinity MetAP-2 covalent inhibitor, ovalicin (OVA), was connected to
IκBα, generating a bifunctional targeting system termed proteolysis-targeting chimeric
system (PROTAC-1). This system demonstrated the direct ubiquitination and degradation
of a foreign substrate, MetAP-2, through the chemical control of the endogenous E3ligase SCF system.65 The PROTAC itself was the result of the facile linkage of the
angiogenic MetAP-2 inhibitor OVA to the IκBα peptide via the commercially available
disuccinimidyl suberate-glycine linker using standard FMOC chemistry.
This strategy has provided an alternative technique to interrogate the inner space
of proteome without resorting to the more quixotic mutational or targeted screens used to
generate a specific phenotype. The PRTOAC posttranslational technology has seen
further applications to knock down both the androgen and estrogen receptors using the
IκBα-estradiol

and

IκBα-dihydroxytestosterone

PROTACT-2

and

PROTAC-3,

respectively, with the SCF -TRCP complex.66
β

Alternative E3 domains have also been successfully employed, such as the von
Hippel-Lindau (VHL) tumor suppressor E3-Ligase, which recognizes the central
hydroxylated proline of the seven amino acid sequence: -ALAPYIP- of hypoxia inducible
factor 1α (HIF1α). Under normoxic conditions a proline hydroxylase (PHD) catalyzes
the hydroxylation of the central proline in the aforementioned seven-mer of HIF1α. The
VHL recognizes the modification and constitutively ubiquinates HIF1α until cellular
conditions shift to hypoxic levels where the transcription factor is freed and mobilizes
24

downstream system necessary for cell survival.67 Similar to the SCF complex, the VHL
has also seen use in the knockdown of the steroid hormone receptor using PROTACs
constructed of DHT and estradiol with the hydroxylated HIF1α peptide LAPYI.68
Treatment of breast ERα-dependent breast cancer cells and androgen dependent prostate
cancer cells with these PROTACs, respectively, resulted in cell cycle arrest, inhibiting
the proliferation of both cells lines.68
Although the PROTAC approach provides a novel and robust system for
posttranscriptional control, its limitations are easily realized when comparing the
potential number of therapeutic targets to readily available ligands directed at diseasecausing substrates, oncogenic products, or pathogens.69 Hence, the ability to regulate a
specific member of the proteome through a global application will require the
appropriation of a quality control system inherent to living systems.
Currently, there are methods that target specific proteins for degradation in the
absence of a direct targeting ligand: (i) in Arabidopsis thaliana the hormone auxin can be
used to dimerize a SCFTIR1 complex to an AXR3 transcriptional repressor. When the
repressor is genetically fused to a POI the E3-ligase can promote proteolysis of the fusion
construct.70 (ii) To induce GFP targeted degradation a chimeric FBP from Slmb (a
Drosophila melanogaster FBP) was engineered by fusing the N-terminal of Slmb to a
single-domain antibody (VhhGFP4), which is directed to GFP, YFP, or eYFP.71 This
SCFSlmb-VhhGFP4 fusion E3-ligase targeted GPF constructs in drosophila embryos and was
not only readily accessible to the UPS, but devoid of any deleterious effects upon the
embryos. Interestingly, this method demonstrated the ability to rapidly phenocopy lossof-function mutations on both cytoplasmic and nuclear proteins.71
25

The systems mentioned above necessitate genetic modification to generate a
fusion system capable of targeting a POI. Although such systems remain relevant to the
exploration of protiec structure-function relationships, they don’t address the need to
capture more of the ‘undruggable’ portion of the proteome. To address this, a general
method that utilizes small molecules capable of targeting proteins in the cellular milieu is
necessary. Specifically, this method should examine a quality control system that is
fundamental to the intrinsic nature of all proteins.
This characteristic is apparent within the core of a protein’s tertiary structure,
where the burial of hydrophobic residues generates a cumulative stabilizing force.
However, partially folded or misfolded protein states can lead to the exposure of
unstructured hydrophobic regions that would otherwise be buried in their native states.
These aberrant events can promote aggregation of amorphous aggregates or oligomers in
a concentration specific manner, which can increase the cellular distribution of unfolded
endoplasmic reticulum (ER) and cytosolic proteins.
To protect and sustain protein homeostasis within the cells secretory pathway, the
ER and Golgi apparatus turn to a sentinel intracellular signaling system that monitors
folding and unfolding events: the Unfolded Protein Response (UPR) pathway. Here, the
UPR can coordinate the processing of metastable or misfolded proteins which can be
reprocessed back into the folding cycle or, if proper folding is not restored, they enter the
ER-associated degradation (ERAD) pathway, which prepares the substrate for ERtranslocation and ultimately cytosolic proteolysis via the UPS.72, 73 Should an imbalance
of misfolded proteins continue and overwhelm the ER processing machinery, the UPR
will modulate three main responses: (i) brief attenuation of global translational output via
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PERK/eiF2α phosphorylation, (ii) transcriptional activation of ER protein folding
capacity by up-regulating chaperones and preventing ER-bound mRNA translocation (via
IRE1) while simultaneously increasing the rate of degradation of misfolded proteins (via
ERAD), and (iii) in the event where the first two responses are either prolonged or
disrupted, cell death may be initiated.74, 75
Externally, as opposed to within the ER landscape, the translational production, of
nascent polypeptides is also at risk of misfolding and aggregation. To avoid such
deleterious outcomes and ensure the conformational integrity of proteins and overall
protein homeostasis (proteostasis), cells invest in a plexus of highly specialized
eukaryotic chaperones: HSP40, HSP60 (TriC), HSP70s (BiP), HSP90s, and HSP100s.76,
77

These versatile and structurally unique macromolecules can be mobilized to directly

recognize and bind hydrophobic moieties in an effort to facilitate proper folding or
refolding under ribosomal-mediated proteogenesis and stress-inducible scenarios. In
order to govern a coordinated proteostasis network, synergistic action between multiple
pathways, such as the UPR of the ER and UPS mediated proteolysis, must be inherent
(Figure 1.8).
Manipulation of this protein surveillance system may serve as a potential
mechanism for therapeutic application. Induction of proteolysis by mimicking protein
destabilization through hydrophobic exposure may systematically degrade “hydrophobic
tagged” proteins via the proteasome. Indeed Neklesa et al. have demonstrated the ability
to impersonate a partially denatured or unfolded state of a protein and its subsequent
proteolysis using the HaloTag dehalogenase fusion system. By appending a hydrophobic
adamantane moiety (HyT13) to a haloalkane reactive linker, which possesses high avidity
27

Figure 1.8 The integrated proteostasis network comprised (counterclockwise) of the
trafficking, UPS, remodeling, and aggregation/disaggregation components which
serve to interrogate and mediate protein fate. Under trafficking, approximately 180
chaperones and their adaptors contribute to the production of properly folded systems,
whereas the UPS and autophagy systems possess over 600 and 30 components,
respectively.
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for the HaloTag dehalogenase, excellent translational control of various intracellular
fusion proteins was maintained including transmembrane and zebrafish proteins and
targeted POI’s in tumor burdened mice.78, 79
The functional utility of this system was applied to both in vitro and in vivo
systems targeted against the proto-oncogene, HRAS1, a small GTPase that possess
elevated tumorigenic potency under the absence of intracellular signaling.80,

81

A key

diagnostic attribute of the mutant HRAS1G12V allele is that the ectopic expression of this
gene can produce a transformed phenotype that clearly distinguishes Hras1G12V
expression. Thus, when Hras1G12V expressing cells are incubated under low serum
conditions, their ability to maintain cell-to-cell contact is attenuated and they form
distinct colonies rather than their native monolayer formation.
Moreover, their [Hras1G12V expressing cells] utility is also realized in
immunocompromised mice where these cells are capable of tumor formation upon
systemic administration.82 Suppression of the colony forming capability of Hras1G12V in
NIH-3T3 was analyzed with a HA-HaloTag-Hras1G12V fusion and a negative control that
was incapable of binding the haloalkane (HA-HaloTag-Hras1D106A).
Upon treatment with the haloalkane-HyT13, the HA-HaloTag-Hras1G12V
expressing cells had reverted to their native monolayer state, whereas the negative control
produced distinct colonies indicating that their haloalkane-HyT13 tag had successfully
eliminated Hras1G12V fusion protein, in vitro. In vivo examination of this system was
performed in nude mice injected with stably transfected HA-HaloTag-Hras1G12V in NIH3T3 cells with concomitant administration of the haloalkane-HyT13. Tumor formation
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was monitored for 13 days prior to dosing, where members of the treatment group
reported that the average tumor size was 16% of those in vehicle control group.83 While
the HaloTag fusion system has clearly shown the ability to induce hydrophobic mediated
degradation, the system is unable to degrade endogenous proteins unless the HaloTag
system has been fused to the target protein.83
Nonetheless, applying this tour-de-force strategy to a system whose degradation
is mediated by the proteasome, but in an ubiquitin-independent manner, would
demonstrate the direct applicability of hydrophobic-tagging toward endogenous proteins
using readily available and modifiable ligands with out a genetically transfected fusion
construct.
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CHAPTER 2
REGIOSELECTIVE MODIFICATION OF RALITREXED

2.0 INTRODUCTION
The quinazoline-based antifolate Raltitrexed (RTX, ZD1694) exerts its cytotoxic
effect upon the enzyme thymidylate synthase (TS, EC 2.1.1.45) by noncovalent
inhibition, thus preventing dTMP turnover and, ultimately, apoptosis. It was designed to
be a robust, water-soluble analog of the clinically tested CB3717 antifolate, synthesized
to encourage polyglutamylation of it’s gamma-carboxylate in order to retain high
intracellular concentrations and increased cytotoxic potency.1
Several strategies have been applied to generate polyglutamylate analogs of
antifolates via solution or solid phase peptide synthesis (SPPS).2-4 Solution phase
approaches typically necessitate either direct cleavage of the aryl-glutamic acid moiety
from the pterin ring or employ stereospecific enzymatic cleavage of the parent
monoglutamate in order to re-conjugate the (poly)glutamyl tail that was retroactively
synthesized.5, 6
Conversely, the formation of pyroglutamates and their subsequent mono-, di-, and
tri(N15)glutamates followed by condensation to the pterin-aryl group has also been
described for the use as NMR probes.7 Moreover, coupling methods that involved
DCC/NHS or tertiary amines such as triethylamine or 4-methylmorpholine, proved
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incapable of controlled regioselective amidation and, furthermore, can support
racemization under conditions for esterification.8-10 The necessity of regioselective
placement upon antifolate analogs is paramount to their biological activity.11-14
Alternative approaches that don’t involve the deconstruction of antifolate synthons, yet
still maintain the regionselectivity required for biological applications, should focus on
the synthetic modification of the end product of pharmacological agents.15
Specifically, N-protected glutamic anhydrides have proved useful where their
formation activates the carboxylate carbonyls toward specific nucleophilic attack.
Following anhydride formation, activation of the accessible carbonyl is followed by
nucleophilic addition, thus regioselective opening occurs with concurrent release of the
newly modified isomer. The resultant regioselectivity will yield a mixture of α and γ
products that require further isolation and purification.
Altering the reactions conditions can control regioselectivity of N-protected
glutamic anhydrides: polar aprotic or nonpolar solvents can favor γ versus α−selectivity,
respectively, in addition to the steric involvement of both the nucleophile and the Nassociated protecting group.16,

17

The aforementioned routes could easily apply to the

regioselective modification of RTX without altering the pharmacological activity of the
antifolate. By selecting the γ-carboxylate of RTX, multiple synthetic alterations could be
employed. Of specific interest is the facile Cu(I) catalyzed azide-alkyne cycloaddition
(CuAAC) labeling system. Selectively amidating the γ-carboxylate of RTX with
propargylamine (PgA) would render the compound receptive to non-fluorogenic azide
dyes. Upon cycloaddition of the azide-alkyne ligation, the formation of the triazole
complex would produce a highly fluorescent TS specific probe. Here, we describe the
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synthetic route to construct a highly specific thymidylate synthase fluorescent probe
using a known anticancer compound and evaluate its in vitro potential for cellular
localization of TS.

2.1 RESULTS AND DISCUSSION
2.1.0 Synthesis and Characterization of RTXγ -PgA by DCC/NHS Coupling
Initial coupling experiments with 1a and PgA were performed altering between
EDCI and DCC with NHS coupling in order to trap the γ-carboxylate (Figure 2.1).
However, this method produced poor regioselectivity and low yields despite DCC-NHS
stoichiometry. Crude analysis via reverse phase chromatography showed the presence of
excess dicyclourea (DCU), and confirmed the presence of four products (Figure 2.2).
Under UV/Vis detection at 341 nm, and confirmed by LC/MS (data not shown), the crude
material of the DCC/NHS coupling produced four peaks at 1a (23.67 min), 1b (24.69
min), 1b (24.84 min), and 1d: at (25.77 min), resulting in approximately 75% conversion
to both alpha (1b) and gamma isomers (1c) in addition to dual α/γ modification (1d). The
remaining 25% was unreacted starting material (1a) and was recycled for further use
(Table 2.1). The final α/γ content was 1:1.3 or slightly 50% of biologically active product
was generated as measured by all observable UV341 peaks. Purification of the conjugates
was stifled due to the fastidious nature of the acylurea by-product, DCU, necessitating
multiple injections. Nonetheless, the crude products were separated and purified over a
reverse phase semi-preparatory HPLC. Each collected fraction was further analyzed via
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Figure 2.1. General synthetic scheme for the pseudo-selective amidation of 1a using
EDCI and NHS coupling reagents and PgA. Prospective regioselectivities were
verified by LCMS and yields calculated via UV341. (R = aminopterin-thiophene of 1a)
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Figure 2.2 Reverse phase HPLC trace of the crude RTX-PgA conjugates synthesized
using EDC/NHS. All compounds were monitored at 341 nm. (x-axis in minutes)
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Table 2.1 Random regioselectivity was demonstrated using DCC/NHS coupling with
1a and PgA. Multiple substitutions in coupling reagents (DCC/NHS, HOBt/HBTU)
failed to improve selectivity.
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LC/MS for their predicted [M+H]+ at 459, 496, and 533 for 1a-d, respectively (data not
shown). The fractions were then dried and prepped for 1H NMR characterization. In the
interest of characterization and future scaling, only compounds 1a and 1c were analyzed.
Key peaks in the structural assignment of 1a were the diasterotopic methylenes at 2.0 and
2.2 ppm (b,b’) along with 2.4 (a,a’), which were proposed to experience a slight upfield
shift upon amidation at the gamma position, but not the alpha (Figure 2.3) In agreement
with this hypothesis, both sets of methylene protons of 1c produced a slight shift in
addition to no observable change in the lone stereocenter c at 4.5 ppm, thus conferring γconjugation (Figure 2.4).

2.1.1 Synthesis and Characterization of RTXγ -PgA by DCC/DMAP Coupling
To further enhance the selectivity, 1a was subjected to additional steps to ensure
complete γ-regioselectivity without enduring its total synthesis.18 Therefore, the
regioselective opening of glutamic anhydride by PgA using stoichiometric amounts of
DMAP was pursued (Figure 2.5).10 Coupling conditions were sought to completely
dissolve 1a prior to its dilution into dichloromethane (DCM) followed by the drop-wise
addition of DCC in order to slowly form the predicted 1a-anhydride. The 1a-anhydride
reacts at -40 °C with PgA in the presence of DMAP under a jacket of argon. The
resulting 2b and 2c isomers yielded a profound increase in selectivity shifting to 1:9 α/γ.
The crude mixture of compounds 2a-d was quickly identified by HPLC-UV with an
elution order of 2a (23.10 min), 2b (24.31 min), 2c (24.49 min), and 2d (25.67 min). All
compounds were monitored at 341 nm (Figure 2.6) and characterized by LC/MS (data not
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Figure 2.3 1H NMR spectra of 1a. Solvent: CD3OD; Concentration: 6.5 mg mL-1.
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Figure 2.4 1H NMR spectra of 1c. Solvent: CD3OD; Concentration: 3.2 mg mL-1.
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Figure 2.5 General synthetic scheme for the selective amidation via anhydride (1a’) of
1a using DCC and DMAP coupling reagents. Under the polar-aprotic DMF the γcarboxylate was positioned for direct nucleophilic attack by PgA. Prospective
regioselectivities were verified by HPLC-UV. (R = aminopterin-thiophene of 1a)
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Figure 2.6 Reverse phase HPLC trace of RTX-PgA conjugates synthesized using
DCC/DMAP. (x-axis in minutes)
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shown). Given previous characterization (Figure 2.3, 2.4), no attempt was made to
procure their NMR spectra. The concomitant production of the dual modified antifolate
2d was still present. From a synthetic and biological propose, 2d is incompatible as it is
devoted to quenching any potential single modification and it’s α-modification is
pharmacologically inert toward TS. To remove any prospect of forming 2d, PgA
equivalents were paired with 1a (Table 2.2). The synthetic scheme was scaled to 100 µM
and confirmed the reproducibility of achieving enhanced γ-selectivity (1:9 α/γ).
Moreover, compound 2d had completely receded with an accompanying increase in 1a.
Given 3a (21.00 min) is the starting material, it was easily recovered and recycled for
additional syntheses (Figure 2.7). Under DCC/DMAP coupling the ratio of the isomers
3b (22.48 min) and 3c (22.71 min) was shifted from 1:1.3 to 1:9 α/γ by direct cooling to 40 °C in the presence of DMAP and purified under preparatory HPLC to yield 100%
purity 4b with 90% γ-character (Figure 2.7).

2.1.2 Binding Fidelity of RTXγ -PgA
To determine if any of the pharmacokinetic or dynamic parameters of 1a had been
altered, isothermal titration calorimetry was performed on 4b and compared to 1a (Figure
2.8). Both compounds produced a sinusoidal path resulting from their exothermic
interaction with the dUMP-hTS complex. The enzyme was previously analyzed against
dUMP and trace contents of DMF to alleviate any signal from their dilution: no signal.
overlap was detected. Compound 1a bound to the dUMP-hTS complex in a 1:2.4 ratio
with a disassociation constant of 0.068 µM. Both parameters were expected as at
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Table 2.2 Resulting regioselectivity improved under the auspice of a polar aprotic
system, which enabled the regioselective ring opening of the intermediate anhydride
(1a’) to favor the gamma position.
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Figure 2.7 (A) HPLC trace of the crude reaction products using equimolar amounts of
starting material, 1a, and PgA. (B) HPLC trace of post purification of 3b and 3c,
yielding high purity 4b at 90% γ-regioselectivity. (x-axis in minutes)
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Figure 2.8 The top section within each panel is raw exothermic calorimetric output of
each compound recorded over time. The lower section of each panel is the binding
isotherm for each titrant. (A) Bottom panel: binding isotherm of 1a (300 µM) with
dUMP (100 µM) and hTS (15 µM). (B) Bottom panel: binding isotherm of 4b (300
µM) with dUMP (100 µM) and hTS (15 µM).
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saturating conditions hTS can bind both monomers with exceptional fidelity.19 The Gibbs
free energy (-9.8 Kcal), enthalpy (-7588 ± 142 cal mol-1), and entropic parameters (7.47
cal mol-1/deg) reported optimal hydrophobic and hydrogen binding which are all strongly
indicative of selective binding.
However, the behavior of 4b deviated from 1a with the γ-propargylation of its
carboxylate. The addition of the large sp-sp hybridized system may have disrupted
hydrophobic stability of the terminal end of the conjugate, leading to an increase in the
entropic threshold to -17.2 cal mol-1/deg. This, in turn, yielded a poor binding avidity of
4b and increasing the disassociation constant from 0.068 µM to 3.8 µM. Although still
within the binding capability of hTS (ΔG, -7.4 kcal; ΔH, -1.258X104 ± 1195 cal mol-1; N,
1.6), the 4b dUMP-TS system was evaluated spectrophotometrically to evaluate its
inhibitory capabilities. It was demonstrated that 4b still possessed inhibitory capabilities
and functioned as a capable inhibitor (personal communication with Dr. Leslie Lovelace).
The 57-fold decrease in binding suggests that alteration of the gamma unit of 1a
must take into account the enzyme's surface and active site environment. Based on the
crystal structure of 1a with dUMP-TS, the selective placement of the gamma-carboxylate
is seen to coordinate through water-networked hydrogen bonds.20 Although speculative
without a crystal structure, it is likely that inserting the bulky electrophilic alkyne where
the columbic coordination is perturbed is the contributing factor to the deterioration of 1a
binding characteristics.
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2.1.3 In situ CuAAC Reaction with RTXγ -PgA and Az42
Our effort to synthesize a potential biological probe resulted in the synthesis,
characterization, and biophysical evaluation of compound 4b. To determine its in vitro
efficacy, 4b was introduced to TS overexpressing cells (CHL-TS PJZ205/200) using a
novel fluorogenic coumarin dye (5a, 3-azido-7-hydroxycoumarin) which lays dormant
until it undergoes Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC) reaction with a
reactive alkyne [21]. This bioorthogonal reaction is highly specific due to the selective
reactivity between azides and alkynes, which are not endogenous elements in nature.22
(Figure 2.9)
The confocal analysis of the CuAAC reaction was evaluated under various
conditions in which the reagents, 4b, and 5a, were tested for background fluorescence
(Figure can be see in Figure 2.10 and 2.11). Panel C showed a sharp increase in
fluorescence indicating the CuAAC reaction had taken place. Within the overlay of panel
C the propidium iodide nuclear stain clearly demarcates the perimeter of the nucleus and
the presence of the click conjugate 6a is revealed by the pink hue generated from the blue
and red overlap (Figure 2.10). This suggests the CuAAC reaction had taken place while
4b was in a ternary complex with TS and dUMP. Of particular interest are panels F-G,
where both 4b and 5a are incubated as separate components (Figure 2.11).
Neither panels produced any notable fluorescence in the DAPI channel where the
6a conjugate is expected to actively fluoresce after the CuAAC reaction. Moreover, it
was speculated that the combination of the azide-alkyne might possess a low order of
propinquity

and

efficient

ligand-alignment
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undergo

in

situ

CuAAC.23
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Figure 2.9 General scheme for the CuAAC reaction with Az42 (5a) and N3-APOP-FITC (5b) to yield 6a and 6b, respectively.

Figure 2.10 Confocal analyses of the CuAAC reaction with compound 4b and 5a in
CHL-TS PJZ205/200 cells. Conditions: (A) no reagents or dyes. (B) 4b and CuSO4. (C)
4b, TCEP, CuSO4, 5a. (D) TCEP, CuSO4. Panel C clearly indicates a strong presence
of the CuCAA reaction in hTS overexpressing cells. All wells counter stained with
propidium iodide for nuclear representation. Scale bars are 10 µm.
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Figure 2.11 Confocal analyses of the CuAAC reaction with compound 4b and 5a in
CHL-TS PJZ205/200 cells. (E) 4b, TCEP, CuSO4. (F) 4b. (G) 5a. (H) 4b and 5a. All
wells counter stained with propidium iodide for nuclear representation. Scale bars are
10 µm.
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However, given the entropic parameters of 4b, the lack of fluorescence in panel H
(Figure 2.11) confirms that both a reducing agent (TCEP or Sodium Acorbate) and Cu(I)
are required to facilitate the 1,3-Hugsien cycloaddition, which forms the 1,2,3-triazole is
responsible for the fluorogenic activation of 5a.24
To validate the previous findings, the experiments above were repeated in CHL-TS
PJZ205/200 and CHL-TS Null cell lines in addition to the application of a TS-specific
antibody (Ab+TS-647) for co-localization (Figure 2.12). Panel A shows the resultant
fluorescence from the 6a product with overlap noted within the same regions as those
stained with the TS-specific antibody (Figure 2.12). However, panel B, the negative
control, shows some low levels of fluorescence from either 4b or 5a. In comparison with
the TS stain of panel B, it can be seen that the background fluorescence does not correlate
entirely with the signal produced by the TS Ab+TS-647. Thus, it is unlikely that either
component exhibits any characteristics of random fluorescence. Importantly, panels C
and D confirm that fluorescence exhibited in panel A and, therefore, in panel C of figure
2.6, is due to the presence of TS, as the 6a conjugate does not display non-specific
binding or off-targeting capabilities. This is reaffirmed by the lack of signal in both
Ab+TS-647 fluorescent micrographs. (Figure 2.12)
Due to the low background exhibited by 4b in figure 2.8 and the close proximity
with which 5a must aligned with the active alkyne of 4b, an alternative longer
wavelength dye with a extended linker was proposed. The N3-APOP-FITC (5b) linkerdye was used to demonstrate the viability of an alternate probe and to alleviate the
potential for false positive CuAAC between the blue emitting 5a and 4b. The linker
possesses a terminal azide moiety for active CuAAC, which is tethered to two three62

Figure 2.12 Fluorescent confocal micrographs of 6a in CHL TS overexpressing and
null cell lines. (A) 6a CuAAC in TS overexpressing cells are clearly visible and
detected with the +TS 647-conjugated Ab (third column). (B) CuAAC negative
control (no catalysts) shows low background. (C, D) TS null cells show no signal of
any 6a fluorescence or TS (third column). The overlay of C and D includes their
respective DIC. All cells counter stained with propidium iodide (second column).
Scale bar is 10 µm. Taken with 60× Apo Oil.
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methylene spacers with an internal amide and the carboxy-terminus of the linker
conjugated to FITC. In panels A-D a sharp increase in the fluorescence within the DAPI
filter is seen to increase in a concentration dependent manner (Figure 2.13). Although the
GFP channel records the presence of the 5b CuAAC reaction (no background within the
inset for free dye), the same corresponding reaction shows activity in the DAPI filter.
This phenomenon indicates that 4b might be fluorescent, but only in relationship
to the levels external dye is administered and, therefore, is dependent on the CuAAC or
triazole formation. This is because the addition of 4b was constant (25 µM) and free 5b
(insets in all panels) did not produce any activity in either the DAPI or GFP filters.
(Figure 2.13) Potentially, channel overlap, or bleed, appears to occur at the expense of the
CuAAC reaction. However, it stands to be more reasonable to assume the triazole itself
possesses fluorescent properties because, as the threshold of CuAAC rose in proportion
to the amount of azide-dye added, there was an accompanying increase in signal within
the DAPI channel. Provided with this posit, it was pertinent to further investigate the role
of 4b and its potential cross-fluorescence.
In order to investigate the fluorescent relationship between 4b and 5b, flow
cytometry was used to measure their prospective interactions in CHL-TS pJZ205/200 cells
(Figure 2.14). Here, 25 µM of 4b and 5b was applied to cells as the signal and spatial
representation of the dye at this concentration was superior to those at the other three
concentrations seen in figure 2.13. Plot A2 illustrates the CuAAC signal from both the
488 (5b) and 405 (4b) channels, demonstrating that the reaction occurred as evidenced by
the population in the second quadrant, Q2. Interestingly, both negative controls seen in
plots A3 and A4 are free 5b and 4b, respectively, with Q3 of plot A3 occupying the most
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Figure 2.13 Fluorescence micrograph of the CuAAC reaction with 4b and the
extended linker 5b. (A-D) Concentration of 5b varied for each CuAAC rxn
demonstrating maximum signal strength and cellular visualization. Both the DAPI and
GFP filters represent the CuAAC reaction between compound 4b and the dye-linker
with negative controls for the latter (inset). Scale bar is 10 µm. Taken with 60× Apo
Oil lens.
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Figure 2.14 (A) Flow cytometry dot plots for compound 4b and 25 µM 5b dye in CHL-TS pJZ205/200 cells: (A1) Negative control.
(A2) Representative CuAAC reaction. (A3) 25 µM 5b dye. (A4) 25 µM compound 4b. (B) Histogram flow analysis for compound
4b (Alexa Fluor 405-A) in in CHL-TS pJZ205/200 cells demonstrates the fluorescence transmission of 4b (A4, B4) is significantly
altered when compared the transmission generated for the CuAAC reaction (A2, B2). The designation for histograms B1-B4
follows those of the dot plots for A1-A4.

signal and not for 4b. These controls show 4b is not a fluorescent product under the 405channel nor has the azide-dye undergone any type of CuAAC reaction. The relevance to
whether 4b is fluorescent will only be apparent under conditions where (i) triazole
formation occurs without an azide-fluorophore or (ii) triazole formation can only be
detected at a narrow emission that precludes counter fluorescence from either 4b or
azide-associated compounds.
Under CuAAC conditions, histogram A2 shows a distinct shift under the 405channel from the negative control, A2. This suggests that formation of the triazole, and
not 4b itself, is responsible for generating a fluorescent signal. Additionally, histogram
4B, the negative control for 4b, mirrors that of histogram A2, clearly supporting the nonfluorescent nature of free 4b (Figure 2.14). Lastly, it’s unlikely that 4b could exhibit any
proportional signal while bound in a ternary complex with dUMP-TS. The potential to
reach any point of conjugation necessary for fluorescence can only be accessed by the
triazole, as it is presumably solvent exposed, whereas the buried pterin ring system or the
thiophene moiety are deep within the binding pocket of the 6bdUMPTS ternary
complex.

2.2 EXPERIMENTAL
2.2.0 Synthesis and Characterization of RTXγ -PgA by EDCI/NHS Coupling
Dr.’s Jiangli Fan, Yi Chen, and Honglin Li graciously performed the synthesis of
4b for the use of all cell assays. The following is a brief analysis of their synthetic 4b for
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the use of all cell assays. The following is a brief analysis of their synthetic protocol. In a
500 mL round bottom flask, 2.1 mmol (1 g) of 1a was dissolved in 10 mL of DMF and
cooled in a water-ice bath. To the reaction, 2.5 mmol (0.260 g) of NHS and 2.5 mmol
(0.44 g) of EDCI were added. The resulting mixture was stirred will in the ice bath for
0.5 hrs until a white precipitate formed. A solution of PgA (0.124 g, 2.25 mmol) in 5 mL
of DMF was added. The resulting mixture was allowed to come to room temperature and
stirred for 24 hrs. The reaction mixture was poured into water (100 mL) and stirred for 30
min to form a precipitate. The crude product was purified over a RP C18 10.0 x 250mm,
10 µm column at 6 mL min-1using a 25% ACN (0.05% TFA) to 90% gradient in 60 min.
Peaks were detected at 220 nm and confirmed via ESI LC/MS. Fractions were collected,
pooled, and dried under lyophilization to yield 4b as a brown-yellow solid; 1H NMR (400
MHz, CD3OD) δ 1.98 (1H, m) 2.15 (1H, m), 2.31 (1H, m), 2.41 (1H, m), 2.52 (3H, s), 2.5
(1H, d, J = 9.2 Hz), 3.12 (1H, s), 3.89 (1H, s), 3.95 (1H, s), 4.7 (1H, s), 6.0 (1H, d, J = 4.4
Hz), 7.6 (1H, d, J = 8.4 Hz), 7.7 (1H, d, J = 8.2 Hz), 8.1 (1H, s); Compound 1a purchased
from Sequoia Research Ltd.; 1H NMR (400 MHz, CD3OD) δ 2.0 (1H, m), 2.2 (1H, m),
2.0 (1H, m), 2.4 2.0 (1H, m), 3.1 (3H, s), 4.5 (1H, m), 4.66 (2H, s), 5.97 (1H, d), 7.49
(1H, s), 7.5 (1H, d, J = 9.5 Hz), 7.7 (1H, d, J = 8.1 Hz), 8.06 (1H, s).

2.2.1 Synthesis and Characterization of RTXγ -PgA by DCC/DMAP Coupling
To a 100 mL round-bottom flask were added 1a (47 mg, 103 µmol) in 2 mL of
DMF under argon and cooled to 4 °C followed by the drop-wise addition of 6 mL of
DCM with DCC (20 mg, 97 µmol) over 60 min. The flask brought to -40 °C in a dry ice-
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acetonitrile bath and where DMAP (12 mg, 99 µmol) in DCM was added via the septum.
To the flask, the primary amine PgA (6.4 µL, 100 µmol) was added and reaction was run
for 3 hours at -40 °C then allowed to reach to room temperature over night. The reaction
was extracted 2× in 15 mL of water with DCM and pooled using a 250 mL separation
funnel. The pooled water was evaporated under reduced pressure at 52 °C with ACN
until dry. All samples were prepared for analytical and preparatory HPLC-UV using the
corresponding methods. Analytical: Inject 20 µL over a RP C18 4.6 × 250 mm, 5 µm
column from 10-80% ACN with 0.1% TFA at 1 mL min-1 in 45 min, monitoring peaks at
269 and 341 nm. For preparatory purification inject 94 µL over a RP C18 10.0 × 250mm, 5 µm column from 10-80% ACN with 0.1% TFA at 4.7 mL min-1 monitoring peaks
at 269 and 341 nm. Peaks were identified and collect using MassLynx FractionLynx
software.

2.2.2 Enzyme Purification
Thymidylate synthase was partially purified according to the protocol previously
reported.19

2.2.3 Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was performed on a VPITC instrument
(Microcal Corp.) with a 250 µL syringe. All ITC measurements were carried out at in
degassed solutions at 26 °C. Approximately 52, 5 µL injections were made with 6-second
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duration and 120 seconds spacing. The macromolecule (TS) concentration was 15 µM in
50 mM Tris-HCl, pH 7.4 with 1 mM EDTA and 20 µM BME, which is referred to as
“Buffer A.” Titration was carried out in buffer A with the following reagents: 100 µM
dUMP and 300 µM of either 1a or 4b. The data was processed using the manufacturers
software ORIGIN.

2.2.4 Cell Prep
All cells were provided by Dr. Franklin G. Berger (University of South Carolina,
Department of Biological Sciences). All cells were grown in a T75 flask under 10% fetal
bovine serum (FBS) in high glucose Dulbecco's Modified Eagle's medium (DMEM) with
100 U of penicillin-streptomycin (Pen-Strep) at 37 °C and humidified at 5% CO2. Cell
line RJK33.13, a TS-deficient derivative of V79 Chinese hamster lung cells (CHL-TS
pJZ205, CHL-TS pJZ205/200, CHL-TS Null) were grown to confluency and passaged at
either 1:10 or 1:20 with 0.25% trypsin. CHL-TS Null cells were supplemented with 10 µM
thymidine.

2.2.5 CuAAC Assay and Image Analysis with Lab-TEKII Prep
CHL-TS pJZ205/200 cells were seeded at 1×105 cell/well into a Lab-TEKII 8well chamber (Nalgene) that was coated with 10 µg/mL of fibronectin at 4 °C for 24
hours. Cells were incubated for 6 hrs at 37 °C and then prepped for 30 min incubation
with reagents according column A in table 2.3. Immediately after incubations wells were
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Table 2.3 CuAAC conditions for confocal analyses with compound 4b and 5a in CHLTS
PJZ205/200 cells.
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aspirated, washed 2× with phosphate buffered saline (PBS) and fixed with 250 µL of
3.7% paraformaldehyde (pfa) for 10 min at room temperature. After fixation, cells were
washed 2× with PBS and counterstained with propidium iodide (PI) at 2 µL/mL. Cells
were washed 3× with PBS and dye-labeled by sequentially adding reagents according to
columns B→E in table 2.3.
The slide was wrapped in aluminum foil and incubated at room temperature (RT)
for 60 min. The cells were aspirated and wash 3× in PBS. Approximately 10 µL of the
antioxidant 1,4-diazabicyclo[2.2.2]octane (DABCO) was added per well and the chamber
was released and covered with a 22x50 mm glass coverslip and sealed with nail polish.
All data was collected on an Olympus IX81 confocal fluorescent microscope with either
a 10× air objective or 60× apo oil lens.

2.2.6 CuAAC Assay and Image Analysis with 12-well Prep
Glass coverslips were added to a twelve-well plate and washed in ethanol
followed by 3× washes with PBS. Each well was seeded with 1×105 cells and incubated
overnight. All wells were prepped for 30 min incubation with 5a or 5b according column
A in table 2.4 and 2.5, respectively. Immediately after incubations wells were aspirated,
washed 3x with PBS and fixed with 250 µL of 3.7% pfa for 10 min at (RT). After
fixation, cells were washed 2× with PBS and counterstained with PI at 2 µL/mL. Cells
were washed 3× with PBS and dye-labeled by sequentially adding reagents (B→D)
according tables 2.4 or 2.5. The trays were wrapped in aluminum foil and incubated at
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Table 2.4 CuAAC conditions for confocal analyses with compound 4b and 5b in CHLTS
PJZ205/200 and CHL-TS Null cells.
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Table 2.5 CuAAC conditions for confocal analyses with compound 4b and 5b in CHLTS
PJZ205/200 cells to determine relationship between concentration of 5b and image
resolution.
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RT for 15 hrs. The cells were aspirated and wash 3× in PBS. Individual cover slips were
removed and dried and set with 10 µL of DABCO or 15 µL of VectaShield and sealed
with nail polish. All data was collected on an Olympus IX81 confocal fluorescent
microscope with either a 10× air objective or 60× apo oil lens.

2.2.7 Immunohistochemistry with 12-well Prep
Immediately after fixation, cells were washed 3× in PBS at 37 °C and
permeabilized with 0.1% Triton X100 for 5 min. Cells were washed 3× in PBS and
blocked in 10% goat serum with 50 mg mL-1 sucrose and 20 mg mL-1 bovine serum
albumin (BSA, Rockcreek) in PBS for 90 min at RT. Cells were washed 3Χ in PBS and
probed for 60 minutes with hTS primary antibody T-106 [1:40] in 5% goat serum with
1% BSA in PBS.
Cells were washed 3×, 5 minutes each in PBS followed by secondary probe Cy5ab-642 goat anti-mouse at 1:2000 in the same solution as the primary probe. Cells were
washed 3 ×, 5 minutes each in PBS and counter stained with PI at 2 µL mL-1. Cells were
washed with 3× with PBS and prepared for CuAAC reaction according to table 2.4 AND
2.5. The trays were wrapped in aluminum foil and incubated at RT for 15 hrs. The cells
were aspirated and wash 3× in PBS.
Individual cover slips were removed and dried and set with 10 µL of DABCO or
15 µL of VectaShield and sealed with nail polish. All data was collected on an Olympus
IX81 confocal fluorescent microscope with either a 10× air objective or 60× apo oil lens.
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2.2.8 Flow cytometry Cell Prep for CuAAC Reaction
Cells were prepped as previously described in section 2.3.4. Cells were seeded in
a 12-well plate at 1×105 cells per well and incubated at 37 °C at 5% CO2 for 24 hours.
Cells were inoculated with 25 µM 4b in six wells filled with 1 mL DMEM and incubated
for 60 min. Cells were washed with 1 mL, 1× in 37°C PBS and then lifted with 150 µL of
0.25% trypsin for 3 min at 37 °C. Cells were centrifuged at 100 RCF for 3 min, aspirated
and washed with 1% BSA in PBS at 37 °C. Additional centrifugation followed at 200
RCF for three min where the cells were then aspirated and fixed in 100 mL of 3.7% pfa at
37 °C for 15 min at RT. Cells were washed again with 1% BSA in PBS and pelleted at
200 RCF for 3 min followed by permeabilization with 100 µL of Triton X-100 for 15
min. Cells were washed again with 1% BSA in PBS and pelleted at 200 RCF for 3 min
then prepped for CuAAC reaction.

2.2.9 Flow cytometry of CuAAC Reaction
To each positive control 100 µL of 1 mM CuSO4 and 250 µL of 2 mM histidine
were pooled together and added to each well. All wells were then diluted with 240 µL of
PBS followed by 10 µL of 2.5 mM 5b. The CuAAC reaction proceeded upon the addition
of 400 µL of 1 mM sodium ascorbate. The reaction was incubated for 30 min at RT with
no light. Post CuAAC, the samples were washed with 1% BSA in PBS and pelleted at
200 RCF for 3 min. The samples were aspirated and resuspended in 400 µL of PBS and
analyzed immediately.
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CHAPTER 3
ANTIFOLATE-PROTAC INDUCED DEGRADATION OF THYMIDYLATE SYNTHASE

3.0 INTRODUCTION
The importance of protein-protein interactions in regards to the etiology of
disease cannot be understated. The ability to mitigate or disrupt these interactions relies
heavily on the pharmacology of biopharmaceuticals or peptide conjugates.1, 2 Although
examples of efficient small molecule targeted therapies have been shown, the ability to
successfully influence these interaction remains difficult given the immense diversity
protein substrates display on their surface or active site.3-5 Contrary to more classically
targeted systems such as enzymes and transmembrane receptors, protein-protein actions
are not dependent on small pharmacophore interactions. Rather, they undergo reciprocal
interactions that are mediated through spatial recognition of surface exposed noncontiguous amino acids.
A bifunctional molecule that recruits rather than disrupts protein-protein
interaction has potential, should the substrate and the recruiting machinery coalesce to
yield a therapeutic response.6 Such systems have shown great utility in cell free systems,
fusion constructs, and drug-peptide/carbohydrate conjugates.7 Specifically the drugpeptide chimera holds great appeal due to its bioorthogonal capacity and its reliance upon
the endogenous machinery inherent to many cell types, but without any genetic assault.
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This system, qualified as the Proteolysis Targeting Chimera System (PROTACs) asserts
targeted degradation via chemical control over the translational conscripts to which it
targets.8
At one pole of the chimeric compound is a substrate-specific ligand, designed to
actively recruit a protein of interest (POI). Tethered by a chemical linker to the opposite
pole of the chimera is a peptide signal-sequence designed to enlist an ubiquitin-protein
E3-ligase, thus targeting the POI for ubiquitin-dependent proteasomal-degradation.9 The
serviceable nature of the ligase is compounded, given there are over 600 E3-ligases of
which the Skp1-Cullin-F-box (SCF) and von Hippel-Landau (VHL) are more widely
studied.10-12 These systems have asserted direct in vitro protein degradation of steroid
hormone receptors, aminopeptidases, aryl hydrocarbon-receptors, and hypoxia-molecular
switches.8, 10, 13, 14
The VHL E3 ligase holds promising potential in anti-cancer therapy due to its
transcriptional relationship with intracellular hypoxia, a condition known to up-regulate
pro-angiogenic genes.15 The VHL tumor suppressor complex is comprised of elongins B
and C, along with Cullin1 and ring box protein 1 (Rbx1).16 Under normoxic conditions
the complex constitutively ubiquinates hypoxia inducible factor 1α (HIF1α) by
recognition of an internal hydroxylated proline located in a conserved 7-amino acid
sequence.17, 18
Interestingly, coupling the HIV-tat translocation peptide to the HIF1α
oxygen-dependent degradation domain (ODD) facilitates cellular entry with an
accompanying angiogenic response along with induction of glucose transporter-1 gene
expression.19 This suggests that using the prolyl hydroxylation site in foreign
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polypeptides can both serve as a VHL-E3 ligase substrate, and prevent HIFα from upregulating its targeted genes. A candidate substrate for the PROTACs system is de novo
source of the thymidine monophosphate (TMP): human thymidylate synthase (hTS, from
this point on it will be referred to as TS unless otherwise noted).
As an overexpressed substrate in cancer, its potential applicability for PROTAC
intervention is significant due to the following attributes: (i) TS represents a metabolic
“bottleneck” for the pyrimidine TMP, thus presenting a pharmacological opportunity to
induce cell death, (ii) TS possesses a large accessible array of modifiable quinazolinebased TS-directed antifolates. These antifolates can serve as the foundation for the TSdirected portion of the heterobifunctional PROTAC conjugate, and (iii) its [TS]
intracellular stability is regulated by an internal bipartite degron and not direct
ubiquitination.20
Selective chemical remodeling has already been demonstrated in potential TS
targeted antimetabolites though elongation of the [antifolate] methylene bridge or through
cyclopenta[γ]quinazoline diglutamyl arrangements at the carboxy-terminus.21,

22

Of

particular interest is the antifolate raltitrexed (RTX, Tomudex) and its nanomolar affinity
toward TS. Previous attempts to modify RTX and its analogs with glutamic acid
substrates successfully demonstrated the facile synthesis of gamma-modification to the
terminal glutamic residue.23-25 Here we describe our approach to the synthetic
construction and in vitro potential of a gamma-linked TS-degradation directed RTXPROTAC system using the VHL-E3 ligase directed HIF1α signal peptide (Figure 3.1).
By affixing the HIF1α signal to the C-terminal carboxylate of RTX, the Ub-machinery is
postulated to recognize the prolyl hydroxylated-peptide, induce TS-ubiquination and its
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Figure 3.1 A general diagram illustrating the theoretical recognition of TS by the
PROTAC HIFα hydroxyproyl moiety fused to TS bound-raltitrexed. Conferring
substrate identity, the formation of the VHL-TS complex is accomplished with
subsequent polyubiquination via the E2-congating subunit.
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subsequent proteasomal degradation. This approach would prevent TS from escaping Ubindependent degradation, thus asserting intracellular control over the endogenous
mechanism(s) that stabilize TS and promote cell death.

3.1 RESULTS AND DISCUSSION
3.1.1 Synthesis of a TS-targeted PROTAC
Using the ALAPYIP peptide for E3-ligase recognition has been shown to serve
as the minimum identification sequence for the VHL tumor suppressor protein.18 Under
hypoxic conditions HIF1α is not a VHL substrate and is therefore not post transnationally
modified at P564.26 Given that cancer cell lines function under hypoxic environments it
was decided to omit the internal proline residue within the 8-mer-recognition [ALAPYIP]
domain and synthesize the peptide with the VHL recognition residue, hydroxyproline
(O). By circumventing the dependence of the intracellular hydroxylation of the
HIF1α peptide we sought to remove any possibilities of generating an inert VHL
substrate that would fail to result in (poly)ubiquitination. For the design of the TStargeted PROTAC-1 we decided to rely upon the simple scaffolding features that solid
phase peptide synthesis (SPPS) affords (Figure 3.2).27
A glycine trimer was coupled the C-terminus of 2 to generate 3a in order to
confer an unobtrusive linker and produce a stable chemical handle. Based on the crystal
structure of a hyrodxylated HIFα bound to the VCB (VHL, elongin C, and B) complex,
we hypothesized that the peptides structural arcing engendered by both the proline and
hydroxyproline residues should be complimented with a ridged handle that orthogonally
extends from the C-terminus away from the VCB complex (Figure 3.3).18 The
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Figure 3.2 General schemes for the synthesis of both PROTAC-1 and PROTAC-2.
Anatomies of both conjugates are shown with the gamma-carobxylate of raltitrexed
tethered to a linker (blue), which presents the HIFα peptide (green) for VHL-E3
recognition.
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Figure 3.3 (a) Crystal structure of the VCB-COOD complex. The pVHL (blue)
complexed to both elonging B (red) and elonging C (orange) with accompanying
hydroxylated HIFα or carboxy-terminal oxygen-dependent degradation motif
(COOD). Site 1 possesses the primary binding site where the hydroxyl modification to
P564 binds to the pVHL’s Hyp-binding pocket through an extensive hydrogenbonding network mediated by water; whereas site 2 only interacts with one residue
negating any sequence specificity and thus is omitted from the PROTAC sequence.
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chemical synthesis of 4a was completed upon ligation of raltitrexed to the C-terminus of
3a. It’s important to note, that no regioselectivity was conferred through the HOBt/HBTU
coupling and thus both regioisomers are present. HPLC purification yielded 4a
(PROTAC-1) with a 78% recovery from 1 in 76% purity. Control peptides 2 and 3a were
synthesized in parallel to serve as in vitro controls (Figure 3.2). It was reasoned that
triglycine-bridge may attract proteolytic digestion or may confer excessive structural
rigidity that would prevent substrate identification, thus an alternative to the linker in 3a
was examined. Substituting for the triglycine linker, a flexible protease-resistant tworesidue polyethylene glycol-FMOC (PEG) chain was coupled to 2 to give 3b followed by
direct coupling to RTX (4b, PROTAC-2).

3.1.2 PROTAC-1 in vitro Challenge
To demonstrate the inhibitory effects of PROTAC-1 we monitored TS expressing
CHL-TS pJZ205 and overexpressing CHL-TS pJZ205/200 cell lines over a 4-day time
course. PROTAC-1 had a moderate inhibitory effect, when compared to free RTX (IC50
0.002 µM), on CHL-TS pJZ205 cells, producing an IC50 of 0.20 µM (Figure 3.4). The TSoverexpressing cell line showed no effect upon administration of PROTAC-1, confirming
the overabundance of TS had muted any growth inhibition or potential degradation.
To substantiate that growth inhibition was due to the presence of the PROTAC-1,
both growth assays were repeated with a thymidine rescue added. It’s reasoned that
supplying the cell with free thymidine can reverse any deleterious pharmacological action
upon TS, thus preventing a thymineless death. Under the auspice of a thymidine rescue,
both cell lines remained resistant to the pharmacological effect of PROTAC-1,
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Figure 3.4 The IC50 performance of PROTAC-1 in CHL-TS pJZ205 (red) and
pJZ205/200 TS overexpressing cell lines (dark green) with concomitant thymidine
rescues (blue and light green, respectively) as compared to free raltitrexed (light blue,
IC50 = 0.002 µM).
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confirming the inhibition is the result of the interaction between TS and PROTAC-1
(Figure 3.4). Although the rescue corroborated PROTAC-1’s actions upon TS, it was still
unknown if the effects were mediated through ubiquitin-depended proteasomal
degradation or alternate mechanisms of cell death.31

3.1.3 PROTAC-1 Ubiquitin Analysis
To determine the extent of PROTAC-1’s relationship with the VHL ligase, and
thus the Ubiquitin Proteasomal System (UPS), TS expressing CHL-TS pJZ205 cells were
exposed to 1x and 10x the IC50 of PROTAC-1 in the presence of the proteasomal
inhibitor, MG132 (Figure 3.5). In an effort to qualitatively assess the potential
degradation of TS, RTX was used to act as a control due to its inherent ability to stabilize
the TS complex (RTXdUMPTS), thus increasing TS intracellular concentration.
Hence, cells were similarly exposed to 1× and 10× the IC50 of RTX (0.002 µM).
Diminishing signal from TS was not observed in the western analysis under either
concentration analyzed for PROTAC-1 (Figure 3.5A). Rather, each PROTAC-1 TS band
closely paired with its RTX cognate both with and without M132 exposure.
Given the potential stabilizing effect of RTX, we next took measures to
investigate whether the inhibitor effect of PROTAC-1 was attenuated due to poor VHL
recognition and the UPS machinery was only capable of moderate signal suppression.
The lysates were analyzed again under the preceding conditions, but probed for signals of
UPS directed degradation of TS (Figure 3.5B). Under conditions free from MG132, no
signal of TS degradation was apparent. Methods to extend the exposure time of the film
failed to yield any qualitative evidence of PROTAC-1 facilitating the ubiquitination of
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Figure 3.5 Western blot analyses of 1× and 10× PROTAC-1 cell lysates from CHL-TS
PJZ205 cells under MG132 inhibitor. (A) Only non-specific bands above TS (RTXdUMP-TS) were noted with no indication of ubiquitin-promoted proteolysis in the
presence of the proteasomal inhibitor MG132. (B) Lysates were analyzed again, but
with ubiquitin specific antibody. No evidence of TS ubiquitination was realized.
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TS. Because each signal in the western analysis closely resembled the stabilizing features
of RTX, we sought to determine if RTX had been excised and was therefore free to bind
TS. Intracellular stability of PROTAC-1 conjugates 2 and 3a were analyzed in CHL-TS
pJZ205 cells to determine their potential effect upon TS inhibition (Figure 3.6). While
PROTAC-1 reproduced its IC50 potential, no effects were observed for either conjugate 2
or 3a, suggesting that the stabilization effect is due to RTX bound to TS. However, no
evidence in the literature could be located regarding the expression levels of the VHL
ligase in CHL-TS pJZ205 cell lines. To alleviate these concerns, an identical Western blot
analysis was repeated in the human colon cancer cell line HCT116. As with the first
experiment in figure 3.5A, no discernable evidence of TS degradation was present
(Figure 3.7).
Finally, we questioned whether PROTAC-1 was acting in accord of the
pharmacokinetic action of RTX or inducing attenuated levels of degradation in an
ubiquitin independent manner. To evaluate this concern, we measured the half-life of
both RTX and PROTAC-1 over a 24 hr period in HCT116 cells. The dosimetry analysis
for the half-life analyses concluded that PROTAC-1 exhibits a stabilizing effect up on
TS, rendering the conjugate a less potent form of its free-from drug.
To this end, we explored the possibility that the tri-glycine linker was too rigid
and performed a subsequent times course study on PROTAC-2 (Figure 3.8). Curiously,
PROTAC-2 produced a 500-fold increase (> 100 µM IC50) in stabilization in both CHL-TS
pJZ205 and overexpressing CHL-TS pJZ205/200 cell lines compared to its counterpart,
PROTAC-1 (IC50 = 0.20 µM). These results indicated that PROTAC-2 is ineffective due
to the PEG linker. It’s likely that its inherent flexibility and restricted atomic length

92

Figure 3.6 Representative plot for the IC50 of the HIFα peptide (red), HIFα with
glycine linker (blue), and PROTAC-1 (green) versus free raltitrexed (pink, IC50 =
0.002 µM in HCT-116 cells. The lack of inhibitory potential of either the HIFα or
HIFα-GGG peptide demonstrates the necessity of RTX in order to target TS and
induce growth inhibition.
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Figure 3.7 Western blot analyses of 1× and 20× PROTAC-1 IC50 concentration in
HCT116 cells under MG132 inhibitor. No evidence of PROTAC-1 induced
degradation of TS is apparent. All bands report RTX stabilized TS complexes.
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Figure 3.8 Half-life analysis of PROTAC-1 in HCT116 during 24-hour exposure to
cyclohexamide. (A) Western blot analysis of control cells (red) yielded within the
range of wtTS half-life (9.6 hrs) while PROTAC-1 (blue) mirrored the stabilizing
effect of free raltitrexed (green). (B) Graphical representation of Western blot
demonstrating the stabilization effect of PROTAC-1.
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disrupts the conformational entropy required for proper ligand-active site docking.
Provided that others have been unable to show TS in an ubiquitinated state, the assertion
that TS follows an ubiquitin-independent proteasomal degradation pathway, stands.32

3.2 EXPERIMENTAL
3.2.1 General Procedure for Solid Phase Peptide Synthesis of PROTAC-1
To a 20 mL reactor cartridge was added Wang-Gly-Fmoc resin (330 mg, 0.20
mmol) followed by solvation in DMF. A fresh solution of 20% piperidine in DMF was
added to the reactor and agitated for 30 min. The resin was then filtered and washed with
DMF (3 × 5 mL) and filtered again. The following is the general procedure for each
Fmoc-amino acid coupling: The resin was washed (3 × 5 mL) in DMF and filtered. To
separate 50 mL flask was added Fmoc-amino acid (4 eq, 2.4 mmol), HBTU (2.9 eq, 1.74
mmol), NMM (4 eq, 2.4 mmol).
The reagents were dissolved in 10 mL of DMF, transferred tot he reaction
cartridge and agitated for 45 min. A Kaiser test was administered to determine reaction
completion.29 The resin was washed (3 × 5 mL) in DMF and filtered. The resin was
deprotected in 20% piperidine in DMF and agitated for 45 min after which a second
Kaiser test was performed. The residues were added in the following order: Fmoc-Proline
(×2), Fmoc-Isolucine, Fmoc-Tyrosine, Fmoc-Hydroxyproline (×2), Fmoc-Alanine,
Fmoc-Leucine, Fmoc-Alanine for 2, Fmoc-Glycine (3×) for 3a.
For the synthesis of 4a in 10 mL flask raltitrexed (2 eq, 0.215 mmol), HBTU (2.9
eq, 1.74 mmol), NMM (4 eq, 2.4 mmol) was dissolved in 7 mL of DMF. Reagents were
transferred to each reaction cartridge with resin-bound deprotected 3a and 3b and
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agitated for 60 min. The resin was washed (3 × 5 mL) in DMF, (3 × 5 mL) DCM, and (3
× 5 mL) in MeOH, filtered, and dried. Peptides 2, 3a, and 4a were liberated from the
resin under 9 mL of 95% TFA in H2O for 2 hrs. The resins were drained and the eluent
was collected. The resins were washed again in 9 mL of 95% TFA and pooled. Each was
subsequently dried under N2 until a yellow or white film appeared. To each was added
ice-cold diethyl ether to form a precipitate. The precipitate was centrifuged at 9,000
RPMs at 4° C for 15 min. The clear eluent was decanted the remaining material was
lyophilized overnight to yield the crude forms of 2 (26.3 mg, 35.3 µmol) 3a, (41.7 mg,
42.2 µmol), 4a (26.5 mg, 18.5 µmol).
All crude peptides were identified and purified by HPLC using a 250 × 10-mm, 5
µm RP C18 column at 5 mL min-1 from 10-65% ACN in 0.1% TFA for 65 min. Injections
of 1.2 mL were monitored at 215, 276, and 304 nm. Fractions were pooled, concentrated,
and lyophilized. Purified products were characterized using ESI LCMS over 150 × 2.0mm, 3 µm RPC18 over 10-65% ACN (0.1% formic acid) gradient in 45 min. Products 2,
3a, and 4 were identified at [M+H]+ 818, [M+H]+ 988.7, and [M+H]+ 1428.5,
respectively.

3.2.2 General Procedure for Solid Phase Peptide Synthesis of PROTAC-2
To a 20 mL reactor cartridge was added Wang-Gly-Fmoc resin (166 mg, 0.10
mmol) followed by solvation in DMF. A fresh solution of 20% piperidine in DMF was
added to the reactor and agitated for 30 min. The resin was then filtered and washed with
DMF (3 × 5 mL) and filtered again. The following is the general procedure for each
Fmoc-amino acid coupling: The resin was washed (3 × 5 mL) in DMF and filtered. To
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separate 50 mL flask was added Fmoc-amino acid (2.9 eq, 0.29 mmol), HBTU (2.9 eq,
0.29 mmol), NMM (4 eq, 0.4 mmol). The reagents were dissolved in 10 mL of DMF,
transferred tot he reaction cartridge and agitated for 45 min. A Kaiser test was
administered to determine reaction completion.29 The resin was washed (3 × 5 mL) in
DMF and filtered. The resin was deprotected in 20% piperidine in DMF and agitated for
45 min after which a second Kaiser test was performed. The residues were added in the
following

order:

Fmoc-Proline

(×2),

Fmoc-Isolucine,

Fmoc-Tyrosine,

Fmoc-

Hydroxyproline (×2), Fmoc-Alanine, Fmoc-Leucine, Fmoc-Alanine for, Fmoc-AEEA
(×2) for 3b. The resin was deprotected in 20% piperidine in DMF and agitated for 45 min
after which it was washed in DMF (3 × 5 mL), DCM (3 × 5 mL) and stored at 4 °C.
For the synthesis of 4b in 10 mL flask RTX (46.5 mg, 0.101 mmol) was dissolved
in 5 mL of DMF. To 45 mL of DCM in a 250 mL round bottom flask the 5 mL solution
of RTX was added and jacketed over argon. The reaction mixture was cooled on ice for
10 minutes and bubbled with nitrogen. In 6 mL of DCM, DCC (21.1 mg, 0.102 mmol)
was dissolved and added drop wise to the reaction over 30 min. The reaction incubated
for 80 min at 4-10 °C under argon and then was brought to -40 °C on dry ice and
acetonitrile. In 2 mL of DCM, DMAP (12.3 mg, 0.100 mmol) was dissolved and added to
the reaction in four 500 µL aliquots. The resin bound 3b was added in 3 mL of DCM and
maintained at -40 °C for three hours and then allowed to reach room temp over night.
Resin bound 4b was transferred to a reaction cartridge and washed in DCM (3 × 5
mL), filtered, and dried. Peptide conjugate 4b were liberated from the resin under 10 mL
of TFA for 2 hrs. The resin was drained and the eluent was collected. The resin was
washed again in 10 mL of TFA and pooled and dried under N2 until a yellow film
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appeared. To the flask was added ice-cold diethyl ether to form a precipitate. The
precipitate was centrifuged at 9,000 RPMs at 4 °C for 10 min. The clear eluent was
decanted the remaining material was lyophilized overnight to yield the crude forms of 4b
(8.9 mg, 6.3 µmol). The 4b crude was identified purified by HPLC using a 250 × 10-mm,
5 µm RP C18 column at 5 mL min-1 from 10-65% ACN in 0.1% TFA for 65 min.
Injections of 1.2 mL were monitored at 269 and 341 nm. Fractions were pooled,
concentrated, and lyophilized. Purified products were characterized using ESI LCMS
over 150 × 2.0-mm, 3µM RPC18 over 10-65% ACN (0.1% formic acid) gradient in 45
min. Purified product 4b (7.7 mg, 86.5%) was identified at [M+H]+ 1402.7 m/z.

3.2.3 General Cell Preparation
All cells were provided by Dr. Franklin G. Berger (University of South Carolina,
Department of Biological Sciences). All cells were grown in a T75 flask under 10% fetal
bovine serum (FBS) in high glucose Dulbecco's Modified Eagle's medium (DMEM) with
100 U of penicillin-streptomycin (Pen-Strep) at 37 °C and humidified at 5% CO2. Cell
line RJK33.13, a TS-deficient derivative of V79 chinese hamster lung cells (CHL-TS
pJZ205, CHL-TS pJZ205/200) were grown to confluency and passaged at either 1:10 or
1:20 with 0.25% trypsin.33

3.2.4 Growth Inhibition Studies for PROTAC-1 and PROTAC-2
To determine the growth inhibition response of compounds 2, 3a, 4a, and 4b,
500,000 cells/well of CHL-TS pJZ205 and CHL-TS pJZ205/200 were each plated in four 6
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well plates and allowed to adhere over 4 hours before drug treatment with ranging
concentrations of each compound were added in duplicate fashion. After five days, the
number of surviving cells was counted with a hemocytometer after counter staining with
Tyrpan Blue and the IC50 determined. The inhibition of the PROTAC conjugates was
generously performed by Karen Barbour (University of South Carolina, Department of
Biological Sciences).

3.2.5 Ubiqutination Analysis for PROTAC-1 in CHL-TS pJZ205 and HCT116 Cells
Cells were plated in 100 mm dishes with 2×106 cells per plate. Cells analyzed for
ubiquitinated products were pretreated with 25 mM MG132 4 hours before RTX and
PROTAC-1 inoculation. Cells were then inoculated with 0.002 and 0.02 µM RTX with
0.2 and 2.0 µM of 4a, to plates both with and without MG132, respectively. Cells were
harvested with a rubber policeman and lysed with M-PER (ThermoFisher) and treated
with 5 mM PMSF, 200 µg mL-1, aprotinin, 100 µg mL-1 pepstatin, and 50 µg mL-1
leupeptin according to manufactures instructions. Crude lysates were centrifuged at
13,000 RPM for 15 min at 4 °C. The extracts were quantified using the Bio-Rad assay
reagent with BSA standard.
Western analysis was performed under standard techniques. The blot was probed
for TS and ubiquitin using a monoclonal antibodies provided by Dr. Franklin G. Berger
(University of Southern Carolina, Department of Biological Sciences). Equal loading of
the lysates was monitored by re-probing the nitrocellulose blots with an anti-actin
monoclonal antibody (Sigma-Aldrich, Clone AC-40). For detection of TS the blots were
visualized using the appropriate species dependent HRP-antibody with the ECL
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chemiluminescence kit from Amersham Biosciences. All blots were run with exposure
controls to correct for film exposure and normalized to actin via densiometric analysis
using ImageJ software.

3.2.6 TS Half-Life Studies for PROTAC-1
The half-life of TS in HCT116 cells under exposure to 2 µM of 4b and 0.2 µM
RTX was assessed according to the protocol previously reported.32
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CHAPTER 4
COMBINATORIAL DEVELOPMENT OF HYDROPHOBIC-TAGGED RALTIREXED

4.0 INTRODUCTION
The traditional routes of probing or modulating protein function have directed
their scope toward alterations at the transcriptional level to engineer or solicit a desired
phenotype. Within this subtext are chemical modifiers that induce or suppress gene
expression either at the level of transcription, translation, or through post-translational
control. These levels of control afford a strict regulation over the dynamic processes that
modulate the invoked protein phenotype. Through RNAi mediated tools, the conditional
knockdown of specific protein phenotypes has emerged as popular and highly desirable
approach for manipulating post-translational events and their resultant gene products.
However, RNAi still cannot afford the spatial-temporal control necessary to achieve a
post-translational effect capable of delivering a sustained degradation response. Thus, to
meet this precise and defined metric, many small molecules have been tailored to
selectively delineate protein function in order to exert a degradation effect, as opposed to
inhibitory, upon their substrates. Selective estrogen-receptor modulators (SERDS) such
as fulvestrant, is a pure agonist that promotes the nuclear degradation of the estrogen
receptor (Er) via proteasomal proteolysis. When co-administered with the proteasomal
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inhibitor bortezomib aggregation of nascent cytosolic Er is promoted activating the proapoptotic mechanism of the UPR.1 Mediated by a series of chaperone complexes, similar
drug-induced ubiquitination-degradation was observed when the tyrosine kinase inhibitor
CI-1033 irreversibly alkylates a cysteine specific to the ErbB2/Her2 receptor.2 These
examples bring specificity to their targets and mediate a global intracellular response
significant enough to induct the UPS pathway through nonnative signaling. While they
demonstrate the therapeutic potential of induced protein degradation, their utility is
narrowed to the intrinsic nature of inhibitors rather than the synergistic exploitation of the
UPS pathway. With the utility of the UPS pathway, a robust system that actively
promotes the ablation of target proteins in an adaptable chemical-induced manner has yet
to emerge.
Several approaches to formulate a proteolytic-inducing small molecule system
have shown promise. Crews and co-workers have developed a heterobifunctional small
molecule capable of inducing proteasomal mediated protein degradation of multiple
proteins of various cellular locations and capabilities. This PROTAC (PROteolysis
TArgeting Chimera) only requires a targeting motif, rather than possessing any inhibitory
action, and a ligand for and E3-ligase separated by a chemically inert linker. The
PROTAC can then form a ternary complex joined by both the ligand specific POI and the
E3-ligase. Thus, the multi-protein E3-ligase ubiquitin-promoting complex can actively
sort and identify foreign substrates for ubiquitination and subsequent proteolysis. This
adaptable system has been used to target and degrade the androgen and estrogen
receptors, peptidase MetAP-2, the immune-regulator FKBP12, and the aryl hydrocarbon
receptor using various E3-ligase specific ligands.3-7
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Recently, a stimuli-responsive PROTAC was developed, where in response to
mitogenic signaling, RTK dimerize and initiate a series of transautophosphyorylation
events through their tyrosine residues within their intracellular domain. This event
recruits a series of substrates that posses PTP and SH2 domains. This phosphoPROTAC
(phosphate PROteolysis TArgeting Chimera) was designed to posses the phosphorylated
tyrosine signaling domain from the NGF receptor, TrkA, and a VHL-binding sequence.
The inactive phosphoPROTAC is phosphorylated by the RTK in response to mitogen
activation. Once the phosphoPROTAC is activated it generates a binding site for the SH2
or PTB-domain-containing effector protein of fibroblast growth factor receptor substrate
2α (FRS2α) and is subsequently polyubiquinated and transported to the proteasome for
proteolysis. Upon treatment of NGF-stimulated PC12 cells the authors observed roughly
a 90% knockdown of the effector/substrate FRS2α.
Encouraged by these results, the authors fabricated another phosooPROTAC
capable of targeting the PI3K receptor using a peptidic sequence from the ErbB2
receptor, which is phosphorylated by ErbB3 in response to neuregulin.8 This model
produced dose-depended toxicity in MCF-7 cells and was successfully applied in a mouse
xenograft model yielding a 40% reduction in tumor volume.8 Although these and the
aforementioned PROTACS have proven to be effective modulators of protein
degradation, they rely on the capability of the E2-ligase to transfer Ub to the POI. In the
case where the ε-amino group is blocked or inactivated by surrounding residues, the E2
ligase is incapable of Ub-conjugation.
A rapid and highly tunable method regulate intracellular concentrations of a
specific protein involves the expression of fusion proteins coupled to an unstable degron108

domain. With in the cell, the degron domain that remains unstable transfers this
instability to its fusion partner. Upon exposure to a degron specific ligand, the domain is
rescued and thus stabilized, whereas the absence of ligand facilitates its proteolysis.9, 10
Although functionally useful, this system necessitates genetic intervention to supply
protein degradation. In the past few years a novel application toward the development of
direct ligand-mediated protein degradation has been introduced. Taking advantage of the
general stabilizing factors that govern protein folding and internal cohesion, some groups
have used various hydrophobic moieties conjugated to known potent inhibitors to pull
down endogenous proteins.11,12
Interestingly, Hedstrom and co-workers have constructed a system that is capable
of Ub-indpendent degradation by affixing a hydrophobic Boc3Arg group to the covalent
(EA, ethacrynic acid) and non-covalent (TMP, trimethoprim) inhibitors of glutathione Stransferase (GST) and E. coli dihydrofolatereductase (eDHFR), respectively. By
mimicking an unfolded protein, through hydrophobic exposure, both EA and EABoc3Arg inactivate GST. However, EA-Boc3Arg yielded a degradation effect, degrading
roughly 80% of GST in whole cells, whereas TMP-Boc3Arg only achieved a 30%
knockdown.11 The adaptable and tunable approach of mimicking hydrophobic exposure
as a means of translational control has also been shown using fusion constructs, which
possess a high affinity for a hydrophobic-tagged ligand (Figure 4.1).12 Under the auspice
of the work performed by Hedstrom and co-workers, we sought to apply hydrophobictagging against human thymidylate synthase (TS), a high value cancer target. In
colorectal cancer (CRC), TS is overexpressed in the crypt cells of the gut where this de
novo source of deoxythymidine monophosphate (dTMP) maintains large pools of
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Figure 4.1 General schematic for the hydrophobic tagging of stable proteins.
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dTMP for DNA replication. This action has subsequently shown to yield routes of
resistance to TS specific inhibitors in established cell lines making it difficult to
manipulate its intracellular levels.13
We previously established the insensitivity of TS against an RTX based
PROTAC, which failed to demonstrate ubiquitination. Thus, investigating the potential of
hydrophobic exposure through TS directed hydrophobically tagged ligand provided the
means to avoid any dependency on either the conjugation or ligation enzymes of UPS. By
working from a known TS inhibitor, raltitrexed, we synthesized a small array of
hydrophobically diversified chemical tags to screen for potential RTX-based compounds
that will recruit the cellular machinery responsible for identifying misfolded proteins and
promote TS-proteasomal degradation.

4.1 RESULTS AND DISCUSSION
4.1.1 Induction of Hydrophobic Exposure to TS Structure Inherent
In order to measure the response of TS to potential hydrophobic exposure, we
induced two point mutations on the solvent exposed helices at residues R115 and D116
(Figure 4.2). Single point mutations for both positions with tryptophan and isoleucine
destabilized TS and decreased its half-life by 30%. However, double point mutation
R115W/D116W and R115I/D116I decreased the half-life of TS by 90%. This level of
degradation indicated that TS is responsive to aberrant hydrophobic exposure, thus
establishing possibility that a TS targeting ligand with the proper level of hydrophobic
exposure may induce proteasomal degradation.
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Figure 4.2 Induction of hydrophobic exposure by site directed mutagenesis of TS
(PDB 1HYV). The solvent exposed residues Arg115 and Asp116 were substituted for
the hydrophobic amino acids Trp and Ille (yellow) in both single and double point
mutations. The double R115W/D116W mutant demonstrated a significant instability
with a 12-fold decrease in half-life as compared to wtTS (6 hrs).
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4.1.2 Raltitrexed Dipeptide Analysis
Quinazolinone based TS inhibitors rely on their poly-γ-glutamate metabolites for
their increased intracellular residency and antitumor activity. It has been established that
these metabolites are more potent inhibitors than their parent monoglutamate compounds.
The addition of one glutamate residue on the γ-carboxyl of 2-desamino-2-methyl-N10propargyl-5,8-dideazafolic acid (ICI 198583) resulted in stronger binding to TS by
approximately 30-fold.14 For these reasons we were interested in the potential inhibitory
effect of raltitrexed (RTX, ICI D1695) in a similar manner. The crystal structure of the
RTX•dUMP•TS complex shows the γ-carboxylate of RTX (1a) is coordinated through
the hydrogen-bond network of water, which resides on the exterior of the binding pocket.
Based on this observation, we designed a small set of RTX-dipeptides that would
represent the various classes of amino acids: acidic (1b, RTX-Glu), basic (1c, RTX-Arg),
hydrophobic-sterically

restrictive

(1d,

RTX-Tyr),

and

hydrophobic-sterically

unrestrictive (1e, RTX-Gly). Each conjugate was prepared under standard Fmoc solid
phase peptide synthesis (SPPS) and their respective regioisomers were purified by HPLC.
Enantiomeric purity of the conjugates was not considered of vital importance provided
that neither stereocenter in the dipeptide affects TS analog fidelity or inhibition, only
serum stability is, in this regard, of vital importance to inhibitor stability.
To evaluate the potential inhibitory effects upon TS, incubation of each conjugate
was performed over a 4-day time course in CHL-TS pJZ205 cells (Figure 4.3). When
compared to 1a, we found that both 1b and 1d produced a significant modulation in the
inhibitory signature of TS with a moderate 5.5 and 14-fold increase in IC50 (Figure 4.3A).
Conversely, both hydrophobic residues were considerably less effective than their
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Figure 4.3 (A) The relationship between the inhibitory characteristics (IC50) of free 1a
and the γ-linked dipeptide conjugates 1b-e. (B) The relationship between the inhibitory
characteristics (IC50) of free 1a and the α-linked dipeptide conjugates 1c’-e’. (C)
General scheme for the synthesis of each α/γ-conjugate of 1a.
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hydrophilic counterparts. Both 1c and 1e yielded a substantial 1450 and 3250-fold
increase in IC50 values compared to 1a. Although not unanticipated for 1e as its
calculated partition coefficient (LogP) was 0.77, indicating hydrophobic character, the
similar result of 1c appeared to be unrelated to this same feature (calculated logP = 1.01). The failure of these two dipeptides to assert any modest inhibitory action could be
for a number of reasons: (i) the hydrophobic character prevented uptake by the RFC, (ii)
without a free γ-carboxylate, neither is a substrate for FPGS, thus their cellular retention
is compromised, and (iii) their direct binding with TS is obstructed due to their anti-polar
nature or steric bulk. Interestingly, when we profiled the α-dipeptide conjugates of 1a,
we found a substantial inhibitory effect for all compounds (Figure 4.3B).
We reasoned that the drastic suppression in IC50 values could not confer the
failure of 1c and 1e as a result of impaired reduced folate carrier (RFC) uptake; rather,
the positional modification of the α-carboxylate may have allowed for FPGS processing
at the γ-position, thus reinstating polyglutamylation. However, previous research with
methotrexate dipeptides revealed the significance behind the role of the α-carboxylate.15
In order to be a substrate for FPGS, the terminal α-carboxylate must be present regardless
of the condition of the initial α-carboxylate.15 Given this evidence, it’s therefore
reasonable to deduce that the enhanced suppressive effect of the α-conjugates is not due
to FPGS processing.
The potency for compound 1d and 1d’ is believe to stem from targeting both TS
and FPGS, although the later is unlikely to target FPGS due to the occlusion of its
terminal α-carboxylate. Previous research has shown that modification of quinazolinone based inhibitors with ornithine act as powerful inhibitor of FPGS and TS.16, 17
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4.1.3 Biological Evaluation of Di-,Tri-, and Tetraglutamates of Raltitrexed
The intracellular metabolism activity of 1a plays a distinct role in both its cellular
residence and substrate avidity. It has been shown that that successive intracellular
glutamylation by FPGS of 1a occurs with 90% conversion to the mono-, di-, tri-, and
tetraglutamates being formed within the first 30 minutes of exposure. The reported
amount of material lost was approximately 30% with the remaining undergoing further
processing to tetra-, penta-, and to a lesser extent, hexaglutamates.18
Based on these results, we synthesized the di-, tri-, and γ-tetraglutamates (1a, 2a,
and 2c, respectively) using standard SPPS followed purification by HPLC. To analyze
their potential to serve as a possible scaffold for hydrophobic tagging, we examined each
conjugates’ TS binding ability and pharmacological impact in CHL-TS pJZ205 cells and
respective lysates (Figure 4.4 and 4.5). Inhibition analysis of 1a, 2a, and 2c showed a
trending increase in resistance as glutamate addition progressed with 2c potency
decreasing 232 fold (Figure 4.4A).
However, the triglutamate conjugate, 2a, resisted this trend and maintained its
potency. Isothermal titration calorimetry correlated with the inhibition analyses and 2a
did not deviate from the inhibition characteristics of the parent monoglutamate (1a).
Finally, the half-life of each conjugate was assessed to determine if the each conferred
the stabilizing effect of 1a. None of the conjugates transformed the extreme stabilization
to the extent of 1a. The di- and tetraglutamate showed marginal reduction the half-life
status of TS with a 2 and 2.4 fold increase in half-life, respectively, with conjugate 2a
reporting a 1.7 fold increase (Figure 4.5).
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Figure 4.4 (A) The effect of conjugating one, two, and three γ-linked glutamic acid
residues upon 1a as measured by the binding ability (Kd) and growth inhibitory
characteristics (IC50) in CHL-TS pJZ205 cells. (B) The effect between α and γ
regiochemistry between the triglutamates 2a and 2b of 1a as measured by growth
inhibition (IC50) in CHL-TS pJZ205 cells. (C) Values of each conjugate measured
against the fold change of 1a.
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Figure 4.5 The relationship between the stability of TS and the effect of successive γglutamylation on 1a. (A) Western blot analyses as measured by the half-life in CHL-TS
pJZ205 cells of di- (RTX-E), tri- (RTX-EE), and tetraglutamates (RTX-EEE) of 1a.
(B) Graphical representation of TS stability (red) against di- (blue), tri- (green), and
tetraglutamates (black) of 1a. (E = γ-glutamic acid)
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To examine the stability of regioisomers between di- and triglutamate conjugates,
we prepared a α-connected triglutamate and assessed its impact on in vitro inhibition of
TS (Figure 4.4B). The α-triglutamate conjugate 2b potency reverted to that of the
diglutamate 1b, highlighting the innate importance of the regiochemical linkage between
residues two and three in the triglutamate conjugate and its relationship to in vitro
efficacy. Furthermore, the biophysical measurements of all conjugates were evaluated to
determine the major driving force behind the stability of 1b (Figure 4.6).
As shown in Figure 4.6, both panels A and B show favorable relationships
between the thermodynamic reaction potential (ΔG) and the general order and alignment
of van der Waals and hydrogen bonding (ΔH) of the RTX conjugates to TS. Maximum
ligand alignment is evidenced by their observed exothermic behavior (ΔH < 0), which
reflects the correct placement of the conjugate at the binding interface (Figure 4.6B).
However, entropic forces become non-ideal as the as the final glutamate or isoleucine
unit is appended to the triglutamate conjugate (Figure 4.6C). This is likely a consequence
chain extension, which increases the disordered nature of chain as residues are added.
Hence, the entropic costs for binding these extended conjugates is high.19

4.1.4 Safety-Catch SPPS Synthesis of Raltitrexed-Triglutamate-Hydrophobic Tags
Based on our synthetic efforts with polyglutamylation of 1a, we were interested in
building a small library of hydrophobic-tagged compounds with 2a serving as the main
scaffold-binding unit. However, given that traditional Fmoc SPPS methods build from
the amino to the carboxy-terminus, the ability to construct a library based on 2a was
prohibitive. As such, we investigated the potential of the Kenner “Safety-Catch” solid
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Figure 4.6 Biophysical analyses of raltitrexed conjugates by isothermal titration calorimetry against TS and dUMP. (A) The
calculated change in Gibbs free energy (all are exergonic, ΔG < 0), (B) measured change in enthalpy (all are exothermic, ΔH < 0),
and (C) the calculated change in entropy for the binding of each conjugate to the dUMPTS complex, respectively. The
transformation from RTX-EE to RTX-EEE illustrates the increase in disorder (ΔS > 0) as related to their binding and their increase
in length and size (PgA), which follows a concomitant decrease in enthalpy for those conjugates (B, C).

phase support (Figure 4.7).20 The alkanesulfonamide handle was quantitatively charged to
high

loading

aminomethyl

resin

using

commercially

available

3-

carboxypropanesulfonamide. Gram quantities for the Safety-Catch (5) resin were
prepared using standard DICI (N,N’-diiso-propylcarbodiimide) and HOBt (Nhydroxybenzotriazole) coupling conditions monitored by a bromophenol blue test (Figure
4.8).21 Linker oligomerization does not occur as the alkanesulfonamide linker is
unreactive to HOBt esters.22 Optimization of the first Fmoc-Glu-OtBu with high loading
efficiency

was

initially

preformed

at

low

temperatures

with

PyBOP

[bromotris(pyrrolidino)phosphonium hexafluorophosphate] and a tertiary base i-Pr2EtN
(Diispropylethylamine) as acylation with HATU reportedly leads to significant levels of
racemization.22
Loading efficiencies for coupling of the first Fmoc-Glu-OtBu (6) produced
extremely low yields for the first charge, with no improvement upon a second charge.
Continued efforts to increase yields were examined by increasing the reaction
temperature to -20 °C from -40 °C, using DMF to fully swell the resin, and increasing the
equivalents of PyBOP and Fmoc-(GluOtBu) (Table 4.1, entry 2). Additional efforts were
made to maintain the swelling properties of the resin using DMF with reaction volume
restriction did not abrogate the low yields. Questioning the reactivity of our
alkanesulfonamide support we switched to commercial Aryl safety-catch resin, however,
results did not improve (Table 4.1, entry 3)
Although reports state that the active intermediate during coupling with PyBOP at
low temperature is the O-acyl phosphonium adduct, we found that coupling to an
extended methylene bridged carboxylate did not warrant low temperatures.23 We then
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Figure 4.7 General scheme for the Kenner safety-catch resin and the alkanesulfonamide linker (1) with subsequent acylation (2),
activation (3) and release of the peptide conjugate through nucleophilic displacement by a potent primary amine (4).
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Figure 4.8 General scheme for building raltitrexed triglutamate scaffold. (i & ii) FMOC-Glu-OtBu (8 eq), PyBop (8 eq), DIPEA
(14 eq), RT, 15 hrs; (iii) 50% piperdine in DCM, 3x 5-10 mg 1 hr Abs @ 301 nm; (iv) RTX (5 eq), PyBOP (5 eq), DIPEA (10 eq),
2-4 hrs (v) ICH2CN (20 eq) in NMP, RT, 24 hrs; (vi) 5 eq of HyT in 5% DMF in THF, 25 °C, 16 hrs. (1a, RTX = raltitrexed)

Table 4.1 Preliminary Safety-Catch reaction parameters. Abbreviations: AlkaneS = Alkanesulfonaminde; ArylS:
Arylsulfonaminde; DIPEA = diisopropylamine; CHCl3 = chloroform; DMF = N’,N’-dimethylformamide; RT = room temperature;
N/A = not applicable; DICI = N,N’-diisopropylcarbodiimide; HOBt = N-hydroxybenzotriazole; PyBOP =
bromotris(pyrrolidino)phosphonium hexafluorophosphate.
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compared the same reactions using 0.044 mmol of resin under both -20 °C and room
temperature to generate a 13% and 58% yield, respectively (Table 4.1, entry 4). The
reaction was duplicated and charged twice to improve yields to 68% (Table 4.1, entry 7).
Given the moderate increase in substitution, entry 4 was examined for additional
coupling followed by Fmoc cleavage (7) managed to stabilize coupling yields (57%)
(Table 4.1). Further optimization was not carried out and raltitrexed (8) was coupled
under lower equivalents followed by ICH2CN activation (9). The conjugate was cleaved
from the resin using 1 equivalent of PgA to yield pro-RTX-EE-PgA (43%).
Encouraged by our improvements, we decided to use the Quest210 synthesizer to
meet our combinatorial needs. Our initial attempt at primary coupling of Glu-OtBu-OH
was met with low yields (~20%), although a second and third charge elevated coupling
up to 87% (Table 4.2, entries 10a-d). In order to improve coupling efficiency for the
attachment of the second glutamic acid the incubation time was increased to 27 hours.
The first round of the second attachment improved average yields to 37%, however a
second charge did not alter coupling (Table 4.2 entries 11a-d).
Low yields were not suitable for further advancement to generate hydrophobictagged library, thus the reaction capacity was increased 5-fold to 0.6 mmol batch
reactions. A dramatic improvement in yield and a reduction in charging, from three to
two, resulted for both glutamate residues (Table 4.2, entries 12 and 13).

4.1.5 Pilot Study for Safety-Catch Raltitrexed-Triglutamate-Hydrophobic Tags
A small pilot library was constructed using seven various hydrophobic tags fitting
with active primary amines based on their known reactivity’s, boiling points, and their
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Table 4.2 Safety-Catch reaction parameters for Quest210. Abbreviations: AlkaneS-E = Alkanesulfonaminde-GluOtBu-OH;
AlkaneS-EE = Alkanesulfonaminde-[GluOtBu-OH] (×2); DIPEA = diisopropylamine; DMF = N’,N’-dimethylformamide; RT =
room temperature; N/A = not applicable; DICI = N,N’-diisopropylcarbodiimide; HOBt = N-hydroxybenzotriazole; PyBOP =
bromotris(pyrrolidino)phosphonium hexafluorophosphate; RTX = raltitrexed.
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calculated partition coefficients (logP) (Figure 4.9A). Each was activated for 24 hrs,
washed and displaced with nucleophile/hydrophobic tags 1-7 (HyT1-7) and purified by
HPLC. A parallel synthesis, performed by our colleague, using selective amidation
methods previously developed by our lab, yielded three highly pure γ-selective
hydrophobic-tagged raltitrexed-conjugates with various polyethylene glycol (PEG)
linkers (Figure 4.9B).
These conjugates were produced to measure the general nature of the glutamic
acid bridge, however, ITC analyses of the three conjugates failed to produce any
thermodynamic results when challenged against the dUMPTS complex (data not
shown). This strongly suggests the ability, if any, of HyT(9-11) to produce a binding
event or exhibit any inhibitory is not promoted by any enthalpic promoted mechanism.

4.1.6 Biological Evaluation of Hydrophobic-Tagged Raltitrexed
The biological impact of RTX-HyT(1-10) were examined over a 4-day time
course in CHL-TS pJZ205 cells (Figure 4.10). Conjugates prepped using the both the
safety-catch resin and selective amidation reported elevated IC50’s, exceeding their parent
compounds (2a and 1a, respectively) cellular efficacy by an average of 2.5×106 fold.
Compounds HyT(7) and HyT(8) produced the lowest inhibition values of 2.3 and 3.7 µM
as shown in figures 4.10A and 4.10B.
The inhibition values were followed up with a half-life assay to determine if the
either of the conjugates had promoted TS destabilization through mimicked hydrophobic
exposure (Figure 4.11). Compound HyT(9) produced a half-life of approximately 14
hours, 1.3 fold higher than the DMSO vehicle (wtTS). However, when compared to 2a
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Figure 4.9 (A) Hydrophobic tags (HyT) used for pilot study with RTX-EE Kenner
safety-catch resin with alkanesulfonamide linker. (B) RTX-PEGn-HyT synthesized via
DCC/DMAP coupling with various pegylated linkers.
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Figure 4.10 Growth inhibition analyses of RTX conjugates with HyT’s 5-7 and 8-10
with triglutamate (A) and pegylated linkers (B), respectively.
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Figure 4.11 (A) Western-blot analysis of RTX-PEG6-HyT(8) half-life. (B) Graphical
representation of the half-life of raltitrexed (blue), RTX-PEG6-HyT(8) (black), and
wtTS DMSO vehicle (red).
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the effect HyT(9) displays is casually lower, indicating its action is the result of TS
destabilization. Additional input in necessary to determine if HyT(9) activity can impose
dose-dependent degradation and if this effect is linked to the proteasome.

4.1.7 Advanced Study for Safety-Catch Raltitrexed-Triglutamate-Hydrophobic Tags
The preliminary results of the pilot study encouraged the development of larger
in-depth analysis, which examined the spatial nature of the HyT’s and their respective
inherent physical properties (logP) and inhibitory capacities (IC50) against TS (Table 4.3).
Group I was predicted to demonstrate an inhibitory relationship directly proportional to
its chain length (logP) due to the increase in potential hydrophobic surface area (Figure
4.12). However, this relationship was not observed, rather HyT(4), the methylated γcarboxylate, yielded the lowest IC50.
Interestingly, HyT(11) with its 9-methylene chain, also produced and IC50
resembling 1b (Figure 4.4). The inhibitory impact by HyT(4) is likely due to the modest
alteration. However, the response to HyT(11) may have maintained the low inhibition
threshold of 1b due to its chain extension, which may not interact directly with the
surface of TS, but allows for surface recognition for degradation. Additional studies
determining each tags roll in degradation is needed.
Further analysis of group II and III compared the effect of methylene spacers (1,
2, or 3) and the effect of benzylic heteroatoms (HyT(19)), along with electron
withdrawing (EWG) and donating groups (EDG), HyT(17, 22) and HyT(18, 21),
respectively. Hydrophobic tags 7, 18, and 20 demonstrated poor inhibition with values
exceeding 10 µM (Figure 4.12). Interestingly, HyT(19), HyT(22), and HyT(23) showed
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Table 4.3 List of corresponding HyT’s used to synthesize their respective RTX-EEHyT(n) conjugates. Yields are based on spectrophotometric measurement of RTX
(1a). Inhibition was measured after 48 hrs in CHL-TS pJZ205 cells. (N/A: Not
Available)
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Figure 4.12 Structural relationship between HyT’s conjugates (RTX-EE-HyT(n)) with
their partition coefficients (logP) and inhibitory capacity toward TS (IC50). (N/A: Not
Available)
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similar results to that of HyT(4) and HyT(11). Hydrophobic tags 22 and 23 indicated that
spacer length might be critical to inhibition when compared to HyT(7), HyT(17), and
HyT(20) with the optimal length set at 2 methylene units (Table 4.12, II and III).
Moreover, strong intra-chain-EDG’s, HyT(21), may also play a role in muting
hydrophobic response. The EDG and EWG of benzylic (single methylene spacers) tags
appear to be deleterious (HyT 17 and 18) with IC50’s reported greater than 5 µM.
Groups V hydrophobic tags possessed some of the lowest IC50’s when compared
to 1b and the other group’s intra-inhibitory results. Here, their “spherical” nature, rather
than the aromaticity displayed by members groups III and IV, appears to parallel their
respective partition coefficients (Table 4.12, V). Although aromatic, the dual nature of
biphenyl moiety of HyT(16) seems to be beneficial and may override its single aryl
homolog HyT(7). Lastly, group VI, a series of potential CuAAC conjugates, and a cyanoterminated aliphatic amine offer modest results with 2× the inhibitory capacity of 1b.
Although it should be noted that HyT(13) does have a surprisingly low IC50 when its
hydrophilic partition coefficient is taken into consideration.
While many of these conclusions are based on the structural activity relationship
(SAR) between the architecture of the hydrophobic tag and both its theoretical logP and
observed IC50, it should be noted that additional analyses should be performed to
substantiate the preliminary SAR. The development of the 1b scaffold, its biological
evaluation, and the construction of the HyT library do, however, provide a useful insight
for further investigation to the degradative potential of hydrophobic tags upon
thymidylate synthase.
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4.2 EXPERIMENTAL
4.2.1 General Cell Preparation
All cells were provided by Dr. Franklin G. Berger (University of South Carolina,
Department of Biological Sciences). Cells were grown in a T75 flask under 10% fetal
bovine serum (FBS) in high glucose Dulbecco's Modified Eagle's medium (DMEM) with
100 U of penicillin-streptomycin (Pen-Strep) at 37 °C and humidified at 5% CO2. Cell
line RJK33.13, a TS-deficient derivative of V79 Chinese hamster lung cells (CHL-TS
pJZ205, CHL-TS pJZ205/200) were grown to confluency and passaged at either 1:10 or
1:20 with 0.25% trypsin.24

4.2.2 TS Half-Life Studies
The half-life of thymidylate synthase in RJK33.13 cells under exposure to HyT(9)
was assessed according to the protocol previously reported.25 The half-life of the
conjugates 1a, 2a, and 2c was generously performed by Karen Barbour (University of
South Carolina, Department of Biological Sciences).

4.2.3 Growth Inhibition Studies
The growth inhibition response of all compounds, unless otherwise stated, was
assessed according to the protocol previously reported.13 This work was generously
performed by Karen Barbour (University of South Carolina, Department of Biological
Sciences). The growth inhibition of RTX-EE-HyT 1-7 and 11-23 in CHL-TS pJZ205 cells
was calculated after 48 hours of triplicate drug conjugate incubation at 37 °C with 5%
humidity using CyQuant Direct Cell Proliferation Assay (Life Technologies, P/N
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C35011). Inhibition analysis was implemented per the manufactures instructions unless
otherwise noted and calculated using Prisim 6 Trial Software.

4.2.4 Solid Phase Peptide Synthesis of Raltitrexed Glu, Gly, Arg, and Tyr Conjugates
Unless otherwise noted, all reactions were carried out using an Argonaut Quest
210 Organic Synthesizer. The following stoichiometric parameters were followed for all
reaction: to a 5 mL reaction cartridge was added Wang-aminoacid-Fmoc (0.05 mmol)
and 4 mL of DMF. The resin was allowed to swell for 60 minutes before it was drained
and deprotected in 20% piperidine in DMF followed by agitation 45 min after which a
second Kaiser test was performed.26 The resin was then filtered and washed with DMF (3
× 5 mL) and filtered again. RTX (1a) (4.0 eq, 0.20 mmol) was dissolved in 5 mL of DMF
with HBTU (2.9 eq, 0.145 mmol), HOBt (2.9 eq, 0.145 mmol), NMM (4.0 eq, 0.20
mmol) then added to the reaction. The reaction was agitated for 2 hrs then filtered and
washed with DMF (3 × 5 mL) then MeOH (1 × 5 mL) and dried.
Raltitrexed-peptide conjugates were liberated from the resin under 2 mL of 98%
TFA in water for 2 hrs. The resin was drained and the eluent was collected. The resin was
washed again in 5 mL of 98% TFA in water then pooled and dried under N2 until a
yellow film appeared. To the flask was added ice-cold diethyl ether to form a precipitate.
The precipitate was centrifuged at 9,000 RPMs at 4 °C for 10 min. The clear eluent was
decanted the remaining material was lyophilized overnight to yield the crude forms of 1b
(18.6 mg, 36.0 µmol), 1e, (30.7 mg, 49.4 µmol) 1c (25.5 mg, 40.9 µmol), and 1d (25.1
mg, 40.8 µmol). Each crude was purified by HPLC using a 250 × 10-mm, 5 µm RP C18
column at 5 mL min-1 from 10-65% ACN in 0.1% TFA for 65 min. Injections of 1.0 mL
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were monitored at 269 and 341 nm. Fractions were pooled, concentrated, and lyophilized.
Purified products were characterized using ESI LCMS over 150 × 2.0-mm, 3 µM RP C18
over 10-65% ACN (0.1% formic acid) gradient in 45 min. Purified γ-products 1b (1.1
mg, 5.2%), 1e (2.3 mg, 7.5%) 1c (1.2 mg, 5.7%), and 1d (1.2 mg, 4.8%) and their
corresponding Purified α-products 1b’ (1.1 mg, 5.2%), 1e’ (3.4 mg, 11.1%) 1c’ (1.2 mg,
5.7%), and 1d’ (1.4 mg, 5.6%) were identified at [M+H]+ 588, 623, 516, and 616 m/z by
ESI LCMS.

4.2.5 Solid Phase Peptide Synthesis of Di-, Tri-, and Tetraglutamates
To a 20 mL reactor cartridge was added Wang-GluOtBu-Fmoc resin (101 mg,
0.05 mmol) followed by solvation in DMF. A fresh solution of 20% piperidine in DMF
was added to the reactor and agitated for 30 min. The resin was then filtered and washed
with DMF (3 × 5 mL) and filtered again. The following is the general procedure for each
Fmoc-GluOtBu acid coupling: To separate 50 mL flask was added Fmoc-GluOtBu (4.0
eq, 0.20 mmol), HBTU (2.9 eq, 0.146 mmol), HOBt (2.9 eq, 0.146 mmol), NMM (4 eq,
0.2 mmol). The reagents were dissolved in 10 mL of DMF, transferred to the reaction
cartridge and agitated for 45 min. The resin was then filtered and washed with DMF (3 ×
5 mL) and filtered again. A Kaiser test was administered to determine reaction
completion.26
To a separate vial, 1a (4.0 eq, 0.20 mmol) was dissolved in 10 mL of DMF
followed by HBTU (2.9 eq, 0.146 mmol), HOBt (2.9 eq, 0.146 mmol), and NMM (4 eq,
0.2 mmol) and then added to the reactor cartridge. The reaction was agitated for 2 hrs
then filtered and washed with DMF (3 × 5 mL) then MeOH (1 × 5 mL) and dried in
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vacuo for 45 minuntes. Raltitrexed-Glu conjugates were liberated from the resin under 10
mL of TFA for 45 minutes. The resin was drained and the eluent was collected. The resin
was washed again in 5 mL of TFA then pooled and dried under N2 until a yellow film
appeared. To the flask was added ice-cold diethyl ether to form a precipitate and was
stored at -20 °C for 30 min. The precipitate was centrifuged at 9,000 RPMs at 4 °C for 10
min.
The clear eluent was decanted the remaining material was lyophilized overnight
to yield the crude forms of 1b (24.2 mg, 41.2 µmol), 2a, (33.2 mg, 46.7 µmol), 2c (29.7
mg, 35.1 µmol), 2b (12.8 mg, 17.8 µmol). Each crude was was purified by HPLC as
previously mentioned in 4.2.3. Purified γ-products were 1b (6.5 mg, 27.3%), 2a, (4.8 mg,
14.3%), 2c (29.7 mg, 12.1%), 2b (3.8 mg, 29.8%) and identified by LCMS as noted in
section 4.2.4 by their [M+H]+ 588, 717, 846, and 717 m/z.

4.2.6 Safety-Catch Resin and RTX-EE-HyT Conjugates
The synthesis of the safety-catch alkane sulfonamide linker and all pilot RTX-EEHyT conjugates were performed according to the protocols previously reported.22
Reactions carried out for Table 4.1 were completed in a 50 mL round bottom glass
whereas all reactions in Table 4.2 were performed on an Argonaut Quest 210 Organic
Synthesizer.
The advanced Safety-Catch study was performed as previously reported with
various alterations.27 Briefly, using the alkanesulfonamide linker from the pilot study, we
successively built the RTX-EE platform and prepared approximately 50 mg (0.020
mmol) for activation (ICH2CN (20 eq), DIPEA (40 eq) in NMP, RT, 24 hrs, no light) and
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release with 5 eq (0.10 mmol) of each HyT’s 1-7 and 11-23 at RT for 64 hrs. Free amines
were captured with high loading tosyl chloride resin (125 mg, 0.3 mmol) and Et3N (84
µL, 0.60 mmol) per reaction in 1 mL of DCM and agitated on an orbital shaker at 150
RPM’s overnight at 27 °C.
The triethylamine salts were free based with K2CO3 (5.2 mmol, 700 mg) for 15
hours at 33 °C at 150 RPM’s. The salts were gravimetrically filtered and washed with
DCM. The filtrates were dried in vacuo, resuspended in 2 mL of Xylene and washed with
2 mL of acetone and filtered again. The filtrate was dried in vacuo and washed with 2-4
mL of BuOH and dried again until dry.
Protecting groups were cleaved with TFA/H2O/TIPS [95:0.5:0.5] for 1 hour then
dried under N2 for 20 minutes. The conjugates were resuspended in 1 mL of 10% ACN in
water then diluted at 1:25 in 100 µL of DMSO. Each conjugate was quantitated by
UV/Vis based on the adsorption of RTX at both 269 and 341 nm, respectively. The bulk
filtrates in 10% ACN in water were subsequently lyophilized, massed, and their yields
calculated (Table 4.3) followed by their resuspension in DMSO to yield a 10 mM
solution of each conjugate for biological evaluation.

4.2.7 Safety-Catch Resin and RTX-PEGn-HyT Conjugates
The synthesis of the RTX-PEGn-HyT conjugates was performed by our colleague,
Enoch Adogla, under Dr. Qian Wang’s mentorship (Department of Chemistry and
Biochemistry, University of South Carolina).
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4.2.8 Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) was performed on a VPITC instrument
(Microcal Corp.) with a 250 µL syringe. All ITC measurements were carried out at in
degassed solutions at 26 °C. Approximately fifty-two, 5 µL injections were made with 6second duration and 120 seconds spacing. The macromolecule (TS) concentration was 15
µM in 50 mM Tris-HCl, pH 7.4 with 1 mM EDTA and 20 µM BME, which is referred to
as “Buffer A.” Titration was carried out in buffer A with the following reagents: 100 µM
dUMP and 300 µM of conjugate(s). The data was processed using the manufactures
software ORIGIN.
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CHAPTER 5

5.0 SUMMARY AND CONCLUSION
Here, we described two approaches’ to systematically degrade human thymidylate
synthase through both an ubiquitin-dependent and independent mechanism. Through our
synthetic endeavors (Table 2.2), we were able to characterize and develop a raltitrexed
(RTX) γ-selective TS-specific probe and pursue in vitro TS tracking through the in situ
application of CuAAC chemistry (Figure 2.12 and 2.14). Applying our previous synthetic
approaches, we used the TS-specific antifolate raltitrexed to synthetically construct a TSHIFα heterobifunctional ligand (PROTAC-1 and -2) that would bind to TS and recruit
the VHL E3-ligase complex for proteasomal degradation. It was hypothesized that
PROTAC-1 and/or -2 would engender the polyubiquitination of TS necessary to induce
ubiquitin-dependent proteasomal degradation. This strategy was perceived to be superior
to the direct systemic administration of antimetabolites used to pharmacologically inhibit
TS action and function independently of the internal TS degron.
We found that neither PROTAC-1 or -2 enabled the targeted ubiquitination of TS,
rather, only moderate inhibition (0.20 µM IC50) of the TS ternary complex (PROTAC1•dUMP•TS) was achieved with half-life stabilities resembling those of free RTX (HalfLife > 24 hrs). The failure of our PROTAC to systematically degrade (through
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ubiquitination) TS could potentially be the result of: (i) the relative short length of the
linker, both triglycine and PEG, may have restricted the presentation of the HIFα signal
peptide and allowed for its non-specific interaction with the surface of TS, (ii) the
regioselectivity of RTX to the linker may have impaired the ability of RTX to
successfully dock with TS as only the γ-carboxylate of RTX has been shown to yield high
binding affinity, or (iii) the lack of active surface lysine moieties on TS has likely
rendered PROTAC’s a moot endeavor, whereas if the VHL E3-ligase were recruited, the
absence of a viable ligation partner (ε-amino group) for the E2-conjugating enzyme
would not accommodate proteasomal degradation via the UPS.
However, the PROTAC served as a translational probe of the innate properties of
TS degradation. Previous results have shown TS degradation is independent to Ub even
the conditions of TS lysine-null mutant. Our results corroborate the inherent resistance of
TS to Ub and substantiate its status as proceeding via ubiquitin-independent proteasomal
degradation.
Notwithstanding, we sought to explore an alternate approach to ligand-directed
degradation of TS. We hypothesized that appending a hydrophobic moiety or “tag” to
raltitrexed functionalize RTX to act as a direct post-translational degradation ligand,
whereas free RTX only stabilizes intracellular TS. Again, using our previous synthetic
efforts, we recruited the Kenner Safety-Catch resin for the construction of multiple TSdirected ligand-based hydrophobic tag conjugates. The Safety-Catch resin was well
suited for our efforts as the acylation at the terminal end of our RTX-EE (1b) conjugate
was impractical under standard N→C solid phase peptide synthesis. With this resin, we
were able to introduce compounds with active primary amines and varying degrees of
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hydrophobicity as determined by their theoretical partition coefficients (LogP).
Furthermore, this approach accommodated the relatively high-throughput requirements
needed to produce complicated compounds with workable yields (60-100%) and apply
them in high-volume manner for their biological evaluation (Table 4.3). We examined 23
prospective hydrophobic tags (HyT) based on their LogP, low molecular weight (> 250
amu), and whether they possessed and active primary or secondary amine. Structurally,
we were interested in the effects of increasing HyT length (surface area) under aliphatic
compounds, aromatic substituents with 1, 2, or 3 methylene spacers from their active
amine, and spherical or elliptical non-aromatic compounds.
The relatively small library was constructed through various stages of method
development and each of the 23 HyT’s was used to generate a RTX-EE-HyT conjugate
capable of targeting TS (Figure 4.8 and 4.12). Post synthesis, we evaluated each
compound in triplicate fashion by monitoring their ability to inhibit cell proliferation in
CHL-TS pJZ205 cells. We found this metric (IC50) to be the most useful as it was easily
scaled for high-throughput analyses and could provide insight as to the potential of each
compound.
Based on our preliminary data, we found no correlation with the increasing
surface area of the aliphatic HyT’s (Figure 4.12, group I) where only the shortest and
longest aliphatic chains recorded inhibition numbers comparable to free 1b (Figure
4.4A). The structure activity relationship (SAR) of benzylated HyT’s (Figure 4.12, group
II and III) indicated that both chain length from the active amine to the benzene moiety
and moderate tailoring of benzene with weak electron withdrawing groups were among
the attributes that contributed to the inhibitory characteristics of each conjugate. The
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remaining tags, group IV and VI, demonstrated excellent and mixed conclusions,
respectively. Group IV consisted of the spherical non-aromatic compounds such as
adamantane. This compound has already demonstrated potential as a hydrophobic tag,
however, the mechanism involved relied upon the genetic assault of the targeted
organism through the direct transfection of a stable fusion construct specifically targeted
by the adamantly-ligand. Under our expertise, we found that the adamantyl moiety and
two of its homologs (HyT’s 12 and 16) reported excellent inhibition values when
compared to the parent compound 1b. Hence, group IV offered the most potential for
further investigation toward the specific involvement of the proteasome.
Taken together, we showed that although TS undoubtedly follows an ubiquitinindependent pathway toward proteasomal degradation, we demonstrated the direct value
in TS degradation through hydrophobic tagging. Unlike several other degradation
methods, which require genetic intervention, hydrophobic tagging would allow for the
direct targeting of TS and circumvent the stabilizing effect of RTX (or other antifolates
with free carboxylates) to potentially promote what would likely be a concentration
dependent reduction of intracellular TS.
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